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ABSTRACT OF THE DISSERTATION 
 
The Role of Reversible Palmitoylation in Regulating Diverse Biological Processes.  
by 
Mohammad Hadi Maktabi 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Cell Biology 
Washington University in St. Louis, 2015 
Professor Kendall J. Blumer, Chair 
 
It is well established that covalent lipid-modification of proteins can play an important 
role in the spatial and temporal organization of many intracellular signaling proteins.  In 
particular, protein palmitoylation, the thioester linkage of a palmitate moiety to a 
cysteine residue, plays a critical role in promoting membrane binding.  It also serves as 
a versatile sorting signal for membrane trafficking and precise microdomain partitioning.  
Classical studies using metabolic labeling have revealed that palmitoylation is dynamic, 
in which many substrates undergo palmitate cycling, and that turnover is regulated by 
extracellular signals. As such, the kinetics of palmitoylation cycling is dependent on the 
interplay between the palmitoyl transferases and thioesterases for efficient and precise 
localization and activity.  Here, I present evidence for the regulation of GPCR signaling 
via protein depalmitoylation as well as the identification of a novel thioesterase that 
could potentially mediate this effect.   
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Chapter 1: Introduction 
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INTRODUCTION  
 
Protein palmitoylation, an overview 
 
Palmitoylation (S-palmitoylation or S-acylation) is a posttranslational modification 
of proteins in which palmitate or other long-chain fatty acids are attached via thioester 
linkage to cysteine residues (1,2).  Protein palmitoylation was first reported more than 
30 years ago (3) but has been underestimated for decades due to the low sensitivity in 
metabolic labeling and the lack of relevant enzymes mediating the reaction.  However, 
recent advances have led to the realization that palmitoylation is a widespread post-
translational modification exploited by eukaryotes, bacteria, and viruses to control 
various biological processes.  Indeed, palmitoylation can have a variety of pleiotropic 
effects on protein activity, localization, sorting, stability, and aggregation and clustering 
(4–8).  Thanks to the advances made in the field, we have come to learn that the 
palmitoylation of substrates are dynamic processes, where palmitate is added and 
removed to affect the subcellular localization and function of palmitoylated substrates.  
These substrates, in turn, are linked to major biological and physiological processes 
where misregulation is often linked to disease states. Indeed, the study of protein 
palmitoylation is particularly important in the signal transduction field because the 
function of many signaling proteins can be altered by dynamic palmitoylation (1,2,7).  
However, given the lack of a robust assay, the mechanism, dynamics, and regulation of 
protein palmitoylation has remained largely unexplored.  Candidate enzymes that 
mediate palmitoylation and depalmitoylation have been reported but remain to be fully 
characterized.  Furthermore, our understanding of the broader significance of dynamic 
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palmitoylation is still limited due to the lack of a clear consensus sequence, the difficulty 
of identifying the subcellular site of palmitoylation, the identity of the relevant enzymes, 
the overwhelming diversity of substrates, and the lack of specific pharmacological 
inhibitors.   
The initial slow rate of progress of the palmitoylation field, as compared to the 
tyrosine phosphorylation field which was discovered a few months after palmitoylation 
(9), has in part been due to two limiting factors: (1) the lack of a robust and sensitive 
assay to study protein palmitoylation and (2) the identity of the enzymes that add and 
remove palmitate were unknown.  Until recently, the only way of studying protein 
palmitoylation involved metabolic labeling of cells with 3H-palmitate followed by a 
lengthy exposure time ranging from days to weeks. Also, for many years it was 
postulated that autoacylation, the spontaneous transfer of palmitate from palmitoyl-CoA 
to cysteine residues, occurs in vivo (4).  Indeed, in vitro non-enzymatic, autoacylation 
has been reported for a number of substrates including Gα subunits (10) and SNAP25 
(11).   However, compelling evidence for enzymatic palmitoylation of proteins has only 
been established recently with the identification of palmitoyl acyltransferases (PATs).  
The number of proteins modified by palmitoylation is large and diverse.  
Examples include signaling proteins (H/N-Ras, Gα proteins, RGS proteins, R7BP, 
GRK6, Cdc42, RhoB, etc.), enzymes (Fyn, Lck, eNos, etc.), ion channels (GluR1/2, 
large conductance (BK) K+ channel, voltage-dependent K+ channel KV1.1, etc.), 
scaffolding proteins (PSD95, GRIP1/GRIP2, etc), cell adhesion molecules (NCAM140, 
integrin α6, etc), and many G protein-coupled receptors (rhodopsin, β2-adrenergic 
receptor, 5HT1A , etc) (7,5).  Despite the many examples, no consensus sequence 
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motif has emerged and this has made it difficult to predict, by sequence alone, new 
substrates for palmitoylation.  To further add to the complexity, proteins can be 
palmitoylated either at their N- or C-terminus or juxta-transmembrane regions  (7).  At 
present, the two common methods to confirm protein palmitoylation is either by the 
mutagenesis of a particular cysteine residue or treating cells with the palmitoylation 
inhibitor 2-bromopalmitate and observing a loss of palmitate labeling.  Although only a 
few enzyme-substrate pairings have been validated, in cases where the palmitoylation 
enzyme is known, knockdown and overexpression of the relevant DHHCs can further 
effect the levels of palmitoylation on the substrates of interest.    
While palmitoylation has typically been studied by monitoring the incorporation of 
radioactive palmitate into the protein of interest, the recent advent of non-radioactive, 
chemical labeling has greatly enhanced this process (5,12–14). The use of palmitate 
analogs increase the sensitivity and speed with which protein palmitoylation can be 
measured.   Also, by coupling chemical labeling with mass spectroscopy, it is now 
possible to identify all the palmitoylated proteins within a given cell type.  Furthermore, 
the recent innovations in the method of detecting protein palmitoylation, used in our 
studies and others, in conjunction with the availability of inhibitors toward 
depalmitoylating enzymes further improves our opportunity to study the mechanism, 
trafficking, and regulation of palmitoylated proteins.  By employing the improved labeling 
approach and recently developed depalmitoylation inhibitors, we were able to present 
compelling evidence for the in vivo role of palmitate turnover on GPCR signaling and 
the identification of a novel depalmitoylation enzyme; the findings from these 
experiments will be presented in the ensuing chapters. 
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Palmitoylation, one of the many types of lipid modification 
 
Proteins can be modified by a variety of lipid groups including myristic acid, 
palmitic acid, palmitoleic acid, steric acid, farnesyl or geranylgeranyl groups, among 
others (Figure 1-1) (5,8).  N-myristoylation, prenylation, and S-palmitoylation represent 
the most common types of lipid modification.  A unique feature of palmitoylation is that, 
unlike the other lipid modifications, it is reversible in which the thioester linkage can be 
readily cleaved by palmitoyl thioesterases (PPTs). Consequently, some proteins 
undergo cycles of palmitoylation and depalmitoylation in a regulated manner.  However, 
it should be noted that a limited number of proteins, primarily secreted proteins such as 
Wnt/Hedgehog/Sonic hedgehog (1), can be irreversibly N-palmitoylated at glycine 
residues but I will focus only on S-palmitoylation or simply palmitoylation henceforth.   
 
 
Figure 1-1.  Representative examples of the types of lipid modification on 
proteins.  
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This figure was adapted from Chamberlain and Shipston 2015 (7).   
 
While palmitoylation is sufficient to promote attachment of otherwise soluble 
proteins to the cytosolic face of the plasma membrane (PM), a number of palmitoylated 
proteins are also myristoylated or prenylated. For instance, the alpha subunit of G 
proteins and certain tyrosine kinases of the Src family (Yes, Fyn, Lck, etc) are co-
translationally modified by the attachment of 14-carbon myristic acid to the amino-
terminal glycine residue (15).  On the other hand, the members of the small GTPases 
Ras and RhoB family contain a C-terminal Cys-Ala-Ala-X (CAAX) motif that are 
modified by proteolytic cleavage of the last three amino acid and carboxymethylation of 
the free carboxyl group of the isoprenenylated cysteine residue (15) (Figure 1-2). 
Although both types of modification increase the total hydrophobicity of the modified 
protein, they are, by itself, insufficient to promote stable membrane attachment. The 
acylation is thought to promote the weak interaction of the modified protein with the 
membrane where it is subsequently palmitoylated on cysteine residues adjacent to the 
myristoylation or prenylation site.  The addition of palmitate to soluble proteins further 
increases its membrane avidity and stably anchors it to the membrane.  This “kinetic 
trapping” model is consistent with the fact that N-myristoyl and prenyl transferases are 
localized in the cytosol and that the initial lipid modification results in a weak and 
transient interaction with intracellular membranes which harbor the enzymes mediating 
protein palmitoylation (16–19).  Thus, in dually acylated proteins, the myristoylation and 
isoprenylation is a prerequisite for palmitoylation in which mutation of the myristoylation 
or prenylation site prevent its subsequent palmitoylation (20).  Palmitoylation work in 
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concert with the other two types of acylation to ensure stable membrane association 
and promote proper trafficking and subcellular localization of these proteins for proper 
function.   
 
Subcellular trafficking of palmitoylated proteins  
 
Protein palmitoylation can have a number of effects on the subcellular distribution 
of soluble proteins.  The primary function is to mediate stable membrane association 
which is enhanced by additional lipid modifications as discussed above.  As such, lipid 
modified proteins are depleted from the cytosol and distributed onto endomembrane 
compartments.  The second effect of palmitoylation is the organization of lipid modified 
proteins to membrane microdomains and subdomains.  Following palmitoylation, the 
modified proteins are trafficked to the plasma membrane via the secretory pathway and 
further compartmentalized in “lipid raft” microdomains, a subdomain of the PM enriched 
with sphingolipids and cholesterol (21).  The sequestration of signaling proteins in lipid 
raft regions and their subsequent lateral redistribution in and out of this region has been 
proposed to be important for the regulation of a number of signaling processes (22).  
The palmitoylation-dependent trafficking of Ras proteins in Figure 1-2 summarizes the 
general process.  Furthermore, cholesterol-rich sub-regions of the Golgi are thought to 
be involved in the sorting of palmitoylated proteins in vesicles bound for the plasma 
membrane (23).  While palmitoylation seems to promote Golgi exit, the route and 
trafficking pathway to the PM is not clear at present.  Lastly, a number of ER proteins, 
such as calnexin, are also palmitoylated and it is hypothesized that palmitoylation 
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serves to organize these proteins to MAM (mitochondrial-associated membranes) 
subdomains of the ER (24).   
 
 
Figure 1-2.   Palmitoylation-dependent cycling of the Ras proteins between the 
plasma membrane (PM) and endomembranes.   
(A) Domain structure of Ras proteins.  The carboxy-terminal CAAX motif and the 
palmitoylation site or poly basic domain are highlighted in blue and brown, respectively.  
(B) Following the initial C-terminal processing, both N- and H-Ras becomes 
palmitoylated by a Golgi-resident, or ER, palmitoyl transferase (RPT) where it is then 
trafficked via the secretory pathway to the inner leaflet of the plasma membrane (PM).  
At the PM, N/H-Ras can further be organized on raft or non-raft microdomains.  
Depalmitoylation by a palmitoyl thioesterase release the lipid modified proteins from the 
PM where they can be repalmitoylated at the Golgi.  K-Ras, on the other hand, bypass 
the Golgi and directly associate with the PM. Abbreviations: AAX (tripeptide of the 
CAAX motif), PFTase (protein farnesyl transferase), Rce1 (Ras and a-factor converting 
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enzyme), Icmt (isoprenylcystein carboxyl methyltransferease), SAM (S-
adenosylmethionine), and RFT (palmitoyltransferease).  The figure is adapted, with 
modification, from Hancock 2003 (25). 
 
Although it would seem that palmitoylation promotes stable membrane 
association, many integral membrane proteins which does not require membrane 
targeting are also palmitoylated, indicating that palmitoylation is not only necessary for 
membrane targeting of soluble proteins but serves additional functions (Figure 1-3). 
Many members of the G protein-coupled receptor (GPCR) family, ion channels, and 
transporters have been reported to be palmitoylated (7,8,5,5).  First, taking GPCRs as 
examples, palmitoylation is necessary for their proper trafficking in which palmitoylation 
deficient mutants are retained in intracellular membranes, most likely in the ER or Golgi 
(5,26–28).  This is consistent with the idea that palmitoylation enzymes are localized to 
these compartments and that palmitoylation is necessary for forward trafficking.  
Another functional consequence of palmitoylation deficiency is exclusion from lipid-raft 
microdomains which serve as concentrating platforms for many signaling processes. 
Additionally, palmitoylation promotes the efficient activation of Gα protein in which 
C341G mutation on β2-adrenergic receptor render it less efficient at stimulating 
adenylate cyclase activity as compared to wildtype receptors (29).  Lastly, palmitoylation 
is thought to control tertiary structure of GPCRs by the proper orientation of the 
cytoplasmic tail relative to the PM (Figure 1-3).  Similar to GPCRs, palmitoylation also 
effect many aspect of ion channel physiology including assembly, trafficking, and 
regulation (30,31).   
10 
 
 
 
Figure 1-3. General examples of palmitoylation sites in transmembrane and 
peripheral-membrane proteins.   
This figure was adapted from Chamberlain and Shipston 2015 (7). 
 
Palmitate turnover 
 
Another notable feature of GPCR palmitoylation is that agonist stimulation 
induces palmitate turnover on not only the receptor but many downstream effectors.  
Activation-induced palmitoylation cycling have been reported for a number of GPCRs 
(including β2-adrenergic, m2 muscarinic acetylcholine, 5-HT4a serotonin, dopamine, 
among others) and is evidenced by increased rate of radioactive palmitate incorporation 
on the receptors following agonist stimulation (19,24–28).  As for downstream effectors, 
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palmitoylation regulates their activity on multiple levels.  For instance, palmitoylation 
increases Gα affinity for binding βγ subunits and to the GPCRs (32).  However, upon 
receptor stimulation, the α subunit dissociates from βγ and is depalmitoylated by a 
palmitoyl thioesterase, presumably APT1.  
There are two hypotheses on the importance of this ligand-induced α subunit 
depalmitoylation: the first is that the activated α subunit is released from the PM to the 
cytosol, thereby terminating signaling, where it can undergo another round of 
palmitoylation at the Golgi and vesicle-mediated trafficking back to the PM (5,33–36).  
Recent studies have reported that Gα subunits, which are thought to stably associate 
with the PM, undergo constitutive shuttling, similar to N-/H-Ras proteins, between the 
Golgi and the PM (37,38).  A second model postulates that the activated α subunit is 
retained at the PM (39) and its catalytic activity regulated by regulators of G protein 
signaling (RGS) protein family which serves as GTPase-activating protein (GAPs) and 
negative regulator of G protein signaling.  Clearly, the mechanism by which the Gα 
subunit is protected from depalmitoylation and the functional consequence of the 
change in subcellular localization remains to be explored.   
 Several members of RGS proteins are also palmitoylated but palmitoylation 
does not seem to be required for membrane association of certain RGS proteins.  
Palmitoylation at Cys2 protects RGS4 protein from degradation by stably promoting its 
PM localization (40,41).  It is also palmitoylated at a second site (Cys95) within the RGS 
domain which has inhibitory effects on RGS4 GAP activity towards Gαi proteins (40). 
The PM targeting of R7 RGS protein family, on the other hand, is mediated by their 
association with R7BP (R7 binding protein) which translocates the R7-Gβ5-R7BP 
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complex from the PM to the nucleus depending on its palmitoylation state (42,43). 
R7BP palmitoylation is dynamic and negatively regulated by Gi/o signaling (43). 
Interestingly, palmitate turnover rates vary for the different proteins. Some 
proteins have a more rapid turnover (half-life of about 20 minutes for N-Ras (5)), while 
others have a more stable association of palmitate (several hours for SNAP25 
(5,44,45)).   The different rates could be attributed to either the number of palmitoylation 
sites on the protein, the accessibility of the substrate to palmitoylation and 
depalmitoylation enzymes, or simply regulated by signaling events.  Alternatively, 
methods of assaying palmitoylation may have limited sensitivity to detect actual turnover 
rates.  Indeed, the palmitate turnover rate on N-Ras is much more rapid as measured 
by subcellular distribution as compared to the traditional biochemical assays (46).  Also, 
the choice of epitope tag and the cell line used can result in different turnover rates.  
Clearly, the advances in metabolic labeling and detection approaches should provide 
substantial insight into the dynamics of protein palmitoylation.   
 
Mechanism and regulation of palmitoylation 
 
As noted earlier, protein palmitoylation was initially thought to be spontaneous 
and driven by local acyl-CoA concentrations.  Autoacylation of many proteins, including 
Gαi (10), SNAP25 (11), β2-adrenergic receptor (47), c-yes (48), among others, has been 
reported in the literature.  Autoacylation of myristoylated Gαi1 was found to be at the 
same cysteine residue as observed in vivo. However, autoacylation is not postulated to 
take place under physiological pH and Acyl-CoA concentrations (49).   Also, the 
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reaction time in some cases are too long to be consistent with the fast palmitate cycling 
observed in vivo.   
The recent discovery of a family of palmitoyl acyltransferase (PATs) in yeast has 
provided compelling evidence against autoacylation (50–53).  It is now well established 
that protein palmitoylation is an enzymatic process mediated by a family of integral 
membrane proteins containing a conserved cysteine-rich domain (CRD) with a 
characteristic Asp-His-His-Cys (DHHC) motif (Figure 1-4)(5,54–56).  The 
overexpression, knockdown, and mutation of the DHHC motif result in altered 
palmitoylation levels of the relevant substrates, thus confirming the in vivo 
acyltransferase activity of DHHC enzymes.  Furthermore, DHHC proteins are conserved 
from yeast to mammals and are sufficient for PAT activity both in vitro and in vivo (5,57). 
Membrane topology prediction indicates that DHHC proteins contain four or more 
transmembrane domains (TMDs) with the DHHC-CRD domain positioned in the 
cytoplasmic side between the second and third TMDs (58). A smaller subset of DHHC 
proteins have additional TMDs and a N-terminal extension containing a series of ankyrin 
repeats.  Lastly, DHHC enzymes are mostly localized to the ER and Golgi and, hence, 
are considered the cellular site of palmitoylation for many proteins.  However, 
determining the exact location has proven difficult because many palmitoylated proteins 
undergo turnover and are subjected to redistribution.  Thus, it is possible for proteins to 
be acylated at more than one location including the PM.  
Additionally, biochemical and genetic evidence has identified the substrates for 
only a few of these enzymes and the large family of mammalian DHHC proteins (23 
enzymes) has prevented investigators from easily identifying other substrates.  There 
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seems to be a redundancy in substrate-enzyme pairing which may be due to the diverse 
palmitoylation motifs, the differential localization of these enzymes that can regulate 
localized palmitoylation events, or that each PAT having activity towards only a limited 
subset of proteins.  It is also likely that some DHHC enzymes may interact with their 
substrate via an accessory protein, as is the case for DHHC9 (form a complex with 
GCP16), while others contain a PDZ-binding motif or ankyrin repeats in their regulatory 
domain to facilitate substrate specificity (5). Further study in the spatiotemporal 
distribution of palmitoylated substrates and identification of substrate-enzyme pairing 
will help to clarify many of these questions.   
 
 
Figure 1-4.  Mammalian DHHC protein family.  
Domain structure of representative DHHC proteins with the DHHC (Asp-His-His-Cys) 
motif necessary for palmitoylation activity highlighted.  Some DHHCs have accessory 
proteins (DHHC9-GPC16) while others have PDZ-binding and ankyrin repeat motifs.  
This figure was adapted from Iwanaga et al, 2009 (5). 
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In addition to de novo palmitoylation or repalmitoylation, palmitoylation cycling 
would involve depalmitoylation which is mediated by protein palmitoyl thioesterases 
(PPTs).  To date, only two classes of enzymes, palmitoyl protein thioesterase 1/2 
(PPT1/2) and acyl protein thioesterase 1/2 (APT1/2), have been shown to catalyze the 
removal of fatty acids from proteins; only APT1 and its closely related homolog APT2 
(64% identical), appear to be involved in the deacylation of cytoplasmically oriented 
intracellular proteins. PPT1 is a lysosomal enzyme and is responsible for the 
depalmitoylation of luminal proteins during protein degradation (59–63).  A recent study 
has demonstrated that APT1, like PPT1, contains a catalytic triad active site composed 
of Ser, His, and Asp and is a member of the α/β hydrolase enzyme family (64). While 
APT1 serves as PPT for a variety of structurally different substrates, there is no specific 
consensus sequence for APT1 recognition and has been shown to have activity toward 
a number of palmitoylated proteins in vitro (Gαi, N/H-Ras, and eNOS) (5,65–67).  
Furthermore, there is little direct evidence for the in vivo role of APT1 in regulating 
protein depalmitoylation.  Indeed, combinations of siRNA knockdown and specific 
inhibitors as well as knockout of APT1/2 in N2a cells, discussed further in the 
subsequent chapters, had no effect on N-Ras palmitate turnover rates in our hands; 
thus, suggesting a role for other, yet unknown, depalmitoylation enzymes in addition to 
APT1 and APT2 (68).   
 
Dysregulation of protein palmitoylation 
 
 Aberrant regulation of S-palmitoylation has been implicated in a number of 
human diseases (7,69,70). The dysregulation could be caused by either mutations 
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affecting the substrate or the palmitoyl transferases and thioesterases.  Firstly, evidence 
suggesting the involvement of cancer-associated palmitoylated proteins (such as Ras, 
Rho, Src, etc) in regulating sustained proliferative signaling, resistance to cell death, 
induction of angiogenesis, and activation of invasion and metastasis is well documented 
(reviewed in (69)) and beyond the scope of discussion here.  Secondly, mutations of 
DHHC enzymes have been associated with a number of diseases including X-linked 
intellectual disability (DHHC9 and15), Schizophrenia (DHHC8), Huntington’s disease 
(DHCC13 and 17), and cancer (DHHC 2, 9, 11, and 14) (7,69). Several DHHC 
mutations or loss-of-function mouse lines have also been developed and exhibit several 
abnormalities including defects in motor coordination, reduced body weight and size, 
hair loss, reduced life-span, hypoactivity, etc. (7). Thus, the reported diseases and 
phenotypes resulting from DHHC enzyme mutations clearly highlight their importance 
for normal physiology.  Lastly, on the depalmitoylation side of the equation, PPT1 
mutations are the underlying cause of infantile neuronal ceroid lipofuscinoisis (INCL) 
which result in the accumulation of granular deposits of palmitoylated peptide 
intermediates in the lysosome (61,7).  
  
Conclusion 
 
In conclusion, palmitoylation is an enzymatic process mediated by palmitoyl acyl 
transferases (PATs) and removed by acyl protein thioesterases (APTs). The attachment 
of the palmitate moiety to both soluble and integral membrane proteins can have a 
number of functional effects including regulating its subcellular distribution, trafficking, 
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and function.  Consequently, the disruption of palmitoylation homeostasis has 
deleterious effects on the normal physiology of palmitoylated proteins. Due to the 
number and variety of proteins being modified by palmitoylation, there has been a 
widespread interest in the (patho)physiological effects of palmitoylation and the 
development of pharmacological modulators to alter palmitoylation dynamic as potential 
therapeutic targets.  However, there is still much to be learned about the activity, 
specificity for substrate, and regulation of palmitoylation and depalmitoylation enzymes.  
As such, the work in the ensuing chapters attempts to address two fundamental 
questions in the field: (1) how are signaling events regulated by reversible 
palmitoylation? and (2) are there any other novel depalmitoylating enzymes that could 
mediate this regulation?   
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ABSTRACT 
 
Reversible attachment and removal of palmitate or other long chain fatty acids on 
proteins has been hypothesized, like phosphorylation, to control diverse biological 
processes. Indeed, palmitate turnover regulates Ras trafficking and signaling. Beyond 
this example, however, the functions of palmitate turnover on specific proteins remain 
poorly understood. Here, we show that a mechanism regulating G protein-coupled 
receptor signaling in neuronal cells requires palmitate turnover. We used hexadecyl 
fluorophosphonate or palmostatin B to inhibit enzymes in the serine hydrolase family 
that depalmitoylate proteins, and we studied R7 regulator of G protein signaling (RGS)-
binding protein (R7BP), a palmitoylated allosteric modulator of R7 RGS proteins that 
accelerate deactivation of Gi/o class G proteins. Depalmitoylation inhibition caused 
R7BP to redistribute from the plasma membrane to endomembrane compartments, 
dissociated R7BP-bound R7 RGS complexes from Gi/o-gated G protein-regulated 
inwardly rectifying K+ (GIRK) channels and delayed GIRK channel closure. In contrast, 
targeting R7BP to the plasma membrane with a polybasic domain and an irreversibly 
attached lipid instead of palmitate rendered GIRK channel closure insensitive to 
depalmitoylation inhibitors. Palmitate turnover therefore is required for localizing R7BP 
to the plasma membrane and facilitating Gi/o deactivation by R7 RGS proteins on GIRK 
channels. Our findings broaden the scope of biological processes regulated by 
palmitate turnover on specific target proteins. Inhibiting R7BP depalmitoylation may 
provide a means of enhancing GIRK activity in neurological disorders. 
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INTRODUCTION 
 
Palmitoylation (S-palmitoylation or S-acylation) is a posttranslational modification 
of proteins in which palmitate or other long-chain fatty acids are attached via thioester 
linkage to cysteine residues (1,2). Hundreds of proteins in eukaryotic cells, including 
monomeric and heterotrimeric G proteins, G protein-coupled receptors, ion channels, 
regulatory enzymes, and scaffold proteins are palmitoylated. Palmitoylation has diverse 
functions, including anchoring hydrophilic proteins to membranes, sorting proteins into 
membrane lipid microdomains, and regulating intracellular protein trafficking, protein-
protein interactions, and degradation. Indeed, palmitoylation has important roles in 
several diseases, including cancer, Huntington disease, and neuronal ceroid 
lipofuscinosis (71–74).  
Unlike other lipid modifications, palmitoylation is reversible under physiological 
conditions. Palmitate is attached to proteins by palmitoyl transferases bearing a 
conserved Asp-His-His-Cys (DHHC) motif and removed by acyl protein thioesterases of 
the serine hydrolase superfamily (1,2,75–78). Being reversible, palmitoylation is widely 
hypothesized, like phosphorylation, to regulate protein function (2,79,80). Indeed, 
palmitate turnover rates on proteins range from minutes (e.g. H- and N-Ras (81,82)) to 
hours (e.g. SNAP-25 (83)), and the palmitoylation status of many proteins is altered in 
response to cell activation (79,80,84–88).  
Despite such evidence, whether palmitate turnover provides a regulatory switch 
that controls protein function remains a central question. This concept is best supported 
by studies of palmitoylated Ras isoforms. Inhibiting depalmitoylation with palmostatin B, 
a small molecule designed to inhibit acylprotein thioesterase 1 (APT1), redistributes H- 
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or N-Ras from the plasma membrane to endomembrane compartments and blunts 
growth factor-evoked activation of Ras on the Golgi apparatus (7). These and other 
findings have indicated that H/N-Ras is depalmitoylated globally by acylprotein 
thioesterases, repalmitoylated by endomembrane-localized palmitoyl transferases, and 
then delivered by anterograde transport to the plasma membrane (21). A variant of this 
model in which palmitoylation occurs both on endomembranes and the plasma 
membrane has been suggested by studies of the dynamically palmitoylated 
postsynaptic scaffold protein PSD-95 (18). Proteomic analysis using alkynyl palmitate 
analogs and pulse-chase analysis has confirmed these findings, identifying a subset of 
enzymatically regulated palmitoylated proteins in mouse T-cells, including Ras family 
GTPases, subunits of heterotrimeric G proteins (including Gs and G13), membrane-
associated guanylate kinases, leucine-rich repeat and PDZ domain (LAP) proteins, and 
other cancer-related scaffolding proteins (22). 
Whereas dynamic palmitoylation occurs on select proteins, many important 
questions remain because the functional consequences of depalmitoylation are nearly 
completely unknown. How widely is palmitate turnover, as distinguished from 
palmitoylation per se, required for function or regulation of specific, palmitoylated 
proteins? What mechanisms determine whether palmitate turnover occurs rapidly or 
slowly on palmitoylated proteins? Does regulated palmitate turnover serve as a switch 
to control protein function? 
To elucidate functions of palmitate turnover in neuronal G protein-coupled 
receptor signaling, we have studied the regulator of G-protein signaling 7 (R7 RGS) 
family (RGS6, -7, -9 –1,-9 –2, and -11) and its control by R7 RGS-binding protein 
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(R7BP), a hydrophilic, palmitoylated SNARE-like protein (23). R7 RGS proteins form 
obligate heterodimers with Gβ5 and function as GTPase-activating proteins that 
accelerate deactivation of Gi/o class Gα subunits (24, 25). When activated allosterically 
upon association with R7BP, R7 RGS-G5 complexes assemble with G protein-regulated 
inwardly rectifying K+ (GIRK) channels to facilitate Gi/o deactivation and consequent 
channel closure (26). Palmitoylation is required for localizing R7BP to the plasma 
membrane, whereas palmitoylation blockade results in transport of R7BP into the 
nucleus (27). At steady state, palmitate turnover occurs rapidly on R7BP, which can be 
negatively regulated by Gi/o signaling (28). Accordingly, palmitate turnover on R7BP 
may provide a mechanism to regulate GIRK activity evoked by Gi/o-coupled receptors. 
Here, we have tested this hypothesis by analyzing the consequences of inhibiting the 
rate-limiting depalmitoylation step of palmitate turnover on R7BP trafficking and 
function. Our studies identify a novel function for palmitate turnover in neuronal cell 
signaling.   
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METHOD 
 
Cell Culture and Transfection: 
Neuro2A cells endogenously expressing RGS7 and Gβ5 but not R7BP, Neuro2A cells 
stably transfected with FLAG-R7BP, and HEK293T cells were cultured as previously 
described (28, 29). Cells were transfected with Lipofectamine 2000 (Invitrogen) 
according to the supplier’s recommendations. Cells were treated with DMSO, 
palmosatin B (Palm B), hexadecylfluorophosphonate (HDFP), and/or cycloheximide 
(Sigma), in OPTI-MEM (Invitrogen) at 37 °C unless otherwise noted. Neuro2A cells 
stably transfected with the APT1 knockdown plasmid pLKO.1-APT1 were selected 
and maintained under puromycin selection. Hippocampal neurons were isolated from 
wild type and R7BP-/- mice as previously described (28).  Neurons were cultured for 14 
d (DIV14) before drug treatment and electrophysiological recording.   
 
Reagents and Antibodies: 
The following antibodies were used: mouse anti-GFP (Abcam), rabbit antiGFP 
sepharose beads (Abcam), mouse monoclonal anti-FLAG M2 (Sigma), mouse anti-
FLAG M2 beads (Sigma), mouse anti-GS28 (BD Transduction Laboratory), Goat anti-
mouse IR800 and Goat anti-rabbit IR 680 (LI-COR), AlexaFluor 488-labeled goat anti-
rabbit IgG and AlexaFluor 568-labeled goat anti-mouse IgG (Invitrogen). Affinity-purified 
rabbit and chicken polyclonal anti-R7BP antibodies have been described previously 
(29). Other reagents were as follows: Palmostatin B (C. Hedberg, Max Planck Institute, 
Dortmund, Germany) Renilla luciferase substrate coelenterazine-h (Nanolight 
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Technology); EDTAfree Complete Protease Inhibitor cocktail tablets (Roche); D-2-
amino-5-phosphonovalerate (DAPV) and 2,3-dihydroxy-6-nitro-7- 
sulfonylbenzo[f]quinoxaline (NBQX) (Tocris); tetramethylrhodamine (TAMRA)-azide 
(Lumiprobe); 17-octadecynoic acid (17-ODYA) (Cayman Chemical Company). The 
following chemicals were obtained from Sigma: DMSO, cycloheximide, 
phenylmethylsulfonyl fluoride (PMSF), poly-D-lysine, tris(2- 
carboxyethyl)phosphine hydrochloride (TCEP), tris-(benzyltriazolylmethyl)amine (TBTA) 
and CuSO4, and puromycin.  
 
Plasmids: 
Plasmids expressing GFP-tagged R7BP, RFP-tagged R7BP, split Venus(1-555)-tagged 
RGS9 and split Venus(156-239)-tagged Gβ5 have been published previously (68). 
Sources of other plasmids expressing various proteins were as follows: GFP-N-Ras and 
GFP-SNAP25 (M. Linder,Cornell University), RFP-Rab5 (P.Stahl, Washington 
University), GABA(B) receptor subunits 1a and 2 (B. Bettler, University of Basel, Basel, 
Switzerland), and GIRK2c (P. Slesinger, Salk Institute). Plasmids expressing GFP-
tagged geranylgeranylated R7BP and FLAG-tagged geranylgeranylated R7BP were 
generated by replacing the wild type R7BP coding sequence for the C-terminal peptide 
LCCLVSS with a sequence coding for CLIL. Plasmids expressing constitutively active 
and RGS resistant Goα was made by replacing coding sequences for Q209 to L and 
G182 to S using site directed mutagenesis. The mouse APT1 and APT2 cDNAs were 
inserted into pEGFP-C1 plasmids to express GFP-APT1 and –APT2. The knockdown 
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targeting sequence in pLKO.1-APT1 for mouse APT1 was 
GCATTCCTTCTAACAGGATTA. The control knockdown targeting sequence in pLKO.1-
Luc for luciferase was GCTGAGTACTTCGAAATGTCC. Duplex RNAs used to knock 
down APT2 were AGCUCCGGACUGUUGUCACACCUGC and 
GCAGGUGUGACAACAGUCCGGAGCUUC.  All plasmids were verified by DNA 
sequencing.   
 
Fluorescence Confocal Microscopy: 
Neuro2A cells seeded on poly-D-lysine (10 µg/ml)-coated coverslips were transfected 
with the indicated plasmids. At 24 h post-transfection, cells were treated 4–6 h as 
indicated and fixed with paraformaldehyde (4%) for 10 min at room temperature. Cells 
were mounted in VECTASHIELD mounting medium (Vector Laboratories) and 
fluorescence images at different wavelengths were captured sequentially on an 
Olympus FV500 microscope using Fluoroview software. Images were adjusted for 
brightness and contrast, assembled as montage, and analyzed using ImageJ software. 
 
Metabolic Labeling, Immunoprecipitation, and On-Bead Click Chemistry: 
Neuro2A cells stably expressing FLAG-R7BP or transiently expressing GFP-N-Ras and 
GFP-SNAP25 were labeled with 25 µM 17-ODYA for 2 h and 6 h for GFPSNAP25 in 
DMEM (Invitrogen) supplemented with 5% dialyzed FBS, 0.1 mM sodium pyruvate, and 
0.1mM non-essential amino acids. Cells were washed with phosphate buffered saline 
(PBS) prior to being chased with media containing 200 µM palmitate in the presence of 
either vehicle (DMSO), Palm B or HDFP for the indicated periods of time. Cells were 
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then washed and suspended in lysis buffer (PBS supplemented with 2.5 µM PMSF, 1x 
EDTA-free Complete Protease Inhibitors, and 1% Triton X100). Cleared lysates were 
immunoprecipitated overnight at 4°C with mouse anti-FLAG beads or rabbit anti-GFP 
beads. After three washes with lysis buffer, beads were suspended in PBS. Click-
chemistry reaction protocols were adopted from previous publications (30, 31). 
Immunoprecipitated samples were reacted with click chemistry reagents (20 µM 
tetramethylrhodamine (TAMRA)-azide, 1 mM TCEP, 100 µM TBTA, and 1 mM CuSO4) 
for 1 h at room temperature with periodic mixing. Reactions were stopped by addition of 
reducing SDS-PAGE sample buffer and boiling for 5 min at 100°C. Samples were 
separated by SDS-PAGE and analyzed by in-gel fluorescence analysis (Typhoon 9400 
laser scanner, GE Healthcare) and Western blotting. Bands of interest were quantified 
using ImageJ (TAMRA fluorescence) or ImageLab (Western blotting) software under 
conditions where detection was demonstrated by control experiments to be in the linear 
range.  
 
Electrophysiology: 
Patch-clamp recordings were performed in whole-cell mode using an Axopatch 200B 
amplifier (Molecular Devices) at room temperature. Experiments were conducted with 
cultured hippocampal neurons 11–13 d after plating, as described previously (26, 32), 
and in transfected Neuro2A cells. Primary neurons and Neuro2A cells were transferred 
from culture medium to an extracellular recording solution containing (in mM): 138 NaCl, 
4 KCl, 2 CaCl2, 1 MgCl2, 10 glucose, 10 HEPES, 0.001 NBQX, 0.01 D-APV, and 0.01 
SR-95531 (gabazine) or 0.01 bicuculline at pH 7.25. Patch pipettes (4–6 MΩ) were filled 
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with a solution containing (in mM): 115 K+ gluconate, 20 KCl, 2 EGTA, 10 HEPES, 2 
Mg2+-ATP, and 0.3 Na-GTP at pH 7.25. Cells were clamped at −70 mV, and access 
resistance (8–12 MΩ) was not compensated. GIRK currents were evoked by GABA(B) 
receptor activation with baclofen (50 µM). GIRK current was recorded in high K+ 
solution with the following composition (in mM): 84 NaCl, 60 KCl, 2 CaCl2, 1 MgCl2, 10 
glucose, 10 HEPES, 0.001 NBQX, 0.01 D-APV, and 0.01 SR-95531 at pH 7.25. In 
these conditions, driving force on K+ yielded inward current at the holding potential of 
−70 mV. Solutions and drugs were applied with a multibarrel, gravity-driven local 
perfusion system. The estimated solution exchange times were 120 ± 14 ms (10– 90% 
rise time), measured by the change in junction currents at the tip of an open patch 
pipette. Where indicated, plasmids expressing GFP-tagged wild type R7BP or R7BPGG 
were transfected into Neuro2A cells 24 h before electrophysiology experiments. Data 
acquisition and analysis were performed with pCLAMP 9.2 software (Molecular 
Devices). Data were processed with Microsoft Excel and presented as mean ± SE. 
Statistical differences were determined using Student’s two-tailed unpaired t test. Offset 
decay times were measured using standard exponential fitting functions. Data plotting, 
statistical analysis, and figure preparations were completed with Prism 5.01 software 
(GraphPad), and Adobe Photoshop.  
 
Bioluminescence Resonance Energy Transfer (BRET):  
Measurement of BRET in intact cells between GIRK2c-Rluc8 and split Venus-tagged 
R7-RGS/Gβ5 complexes was performed as previously described (26). As indicated, 
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cells also were co-transfected with a plasmid expressing FLAG-tagged R7BP. The 
results are expressed as means +/- S.E.M. Statistical comparisons between groups 
were done using Student’s t test.  
 
Activity-based labeling of APT1 and APT2:  
Neuro2A cells were transfected with plasmids expressing GFP, GFP-APT1 or GFP-
APT2, lysed by sonication and treated 30 min with or without reversible APT1- and 
APT2-selective inhibitors (Compound 21 and Compound 1, 10 µM each; ref (33)) and 
probed with an activity-dependent fluorescent probe (PEGylated rhodamine-labelled 
fluorphosphonate; PEG-FP-Rh) for 10 min at room temperature (33). Activity-dependent 
labeling of GFP-APT1 or –APT2 resolved by SDS-PAGE was quantified by 
fluorescence scanning normalized to the level of expressed protein determined by 
quantitative immunoblotting (LI-COR).  
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RESULTS  
 
Inhibition of Palmitate Turnover on R7BP  
Because our prior studies showed that R7BP undergoes palmitate turnover (28), 
we investigated the functions of this process by using Palm B or HDFP to inhibit APT1 
and other enzymes in the serine hydrolase family that mediate protein depalmitoylation 
(9, 22, 34). Because HDFP and Palm B are globally acting irreversible inhibitors of 
depalmitoylation, and Palm B can covalently modify proteins in addition to serine 
hydrolases (9), the experiments described below employed extensive controls to 
determine the specificity of effects observed.  
First, we used established methods (20, 31) to measure the depalmitoylation rate 
of FLAG-tagged R7BP expressed stably at physiological levels with endogenous RGS7-
Gβ5 complexes in neuroblastoma (Neuro2A) cells (29). Control, Palm B-, or HDFP-
treated cells were pulse-labeled with the palmitate analog 17-ODYA, chased with 
conventional palmitate, and lysed at various time points. After immunoprecipitation, 17-
ODYA-labeled proteins were conjugated with an azide-linked fluorescent dye (TAMRA) 
by using click chemistry. TAMRA-labeled FLAG-R7BP was quantified relative to total 
FLAG-R7BP. TAMRA labeling of FLAG-R7BP during the chase indicated the rate and 
extent of depalmitoylation in cells.  
The results indicated that FLAG-R7BP is depalmitoylated by mechanisms 
sensitive to Palm B or HDFP (Fig. 2-1). In control cells, FLAG-R7BP was 
depalmitoylated ∼70% within 1 h (Fig. 2-1A), consistent with prior [3H]-palmitate pulse-
chase labeling studies (28). Palm B or HDFP inhibited depalmitoylation of FLAG-R7BP 
in a dose-dependent manner (Fig. 2-1A). Pulse-chase analysis indicated that HDFP (10 
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μm) slowed the depalmitolyation rate of FLAG-R7BP ∼5-fold (Fig. 2-1B). Likewise, 
depalmitoylation of transiently expressed GFP-tagged N-Ras was markedly inhibited by 
HDFP (Fig. 2-1C). In contrast, transiently expressed GFP-SNAP25 did not undergo 
significant depalmitoylation within 2 h with or without HDFP, consistent with prior 
evidence indicating that palmitate turnover on this protein occurs slowly (19, 35). These 
results indicated that Palm B and HDFP inhibit depalmitoylation of proteins that undergo 
rapid palmitate turnover. 
 
Palmitate Turnover Is Required for Localizing R7BP to the Plasma Membrane  
Because models based on studies of H/N-Ras indicate that palmitate turnover is 
required for localizing palmitoylated hydrophilic proteins to the plasma membrane (21), 
we analyzed the effects of Palm B and HDFP on the subcellular localization of R7BP. 
Neuro2A cells transfected with GFP-R7BP were treated with cycloheximide to block 
new protein synthesis, incubated 2 h with vehicle, Palm B, or HDFP, and then fixed and 
analyzed by confocal fluorescence microscopy. In control cells, GFP-R7BP localized 
primarily to the plasma membrane and to a lesser extent on endomembranes (Fig. 2), 
similar to endogenous R7BP in neurons (29). Following Palm B or HDFP treatment in 
the presence of cycloheximide, pre-existing GFP-R7BP was depleted from the plasma 
membrane and accumulated on endomembrane compartments overlapping with Golgi 
(Fig. 2, A and B) and endosome (Fig. 2C) markers, indicating that redistribution had 
occurred. Redistribution of pre-existing GFP-R7BP following Palm B or HDFP 
administration was confirmed by time-lapse fluorescence confocal microscopy (Fig. 2D). 
Palm B and HDFP had similar effects on FLAG-R7BP stably expressed in Neuro2A 
32 
 
cells at physiological levels (Fig. 2E). Palm B and HDFP increased the extent that RFP-
R7BP and GFP-N-Ras co-localized on endomembrane compartments (Fig. 2F), 
indicating that inhibition of palmitate turnover affects the trafficking of these proteins 
similarly. In contrast, under the same conditions Palm B or HDFP did not affect the 
localization of GFP-SNAP-25 (Fig. 2G) or a form of GFP-R7BP in which its C-terminal 
polybasic region was preserved but its palmitoylation sites (CCLVSS) were replaced 
with the irreversible lipid modification (geranylgeranyl) motif (CLIL) of RhoA (GFP-
R7BP-GG; Fig. 2H). Furthermore, HDFP and Palm B did not impair cell viability or 
organelle (Golgi, endosome) distribution or identity. Therefore, Palm B and HDFP had 
the specific effect of causing proteins that undergo palmitate turnover to redistribute 
from the plasma membrane to endomembranes. 
The time course of R7BP redistribution (t½ ∼60 min) elicited by Palm B or HDFP 
was similar to that shown previously for N-Ras in Palm B-treated cells (7) but much 
slower than the intrinsic rate that palmitoylated proteins translocate to endomembranes 
(seconds to minutes (36)). Presumably, redistribution kinetics of R7BP or Ras reflect the 
relatively slow rate that Palm B or HDFP enters cells and inactivates serine hydrolases 
sufficiently to inhibit depalmitoylation globally.  
Because prior studies showed that constitutively active Goα inhibits R7BP 
depalmitoylation in Neuro2A cells (28), we determined whether expression of a 
constitutively active Goα mutant that does not bind RGS proteins (Goα*; Goα-
Q205L/G184S) affected R7BP localization. Indeed, Goα* caused GFP-R7BP to 
accumulate on endomembrane compartments (Fig. 2I), indicating that R7BP 
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depalmitoylation and intracellular trafficking can be regulated by activated Goα by a 
mechanism independent of RGS-Gα interaction.  
 
Palmitate Turnover on R7BP Regulates Trafficking and Function of R7 RGS-Gβ5 
Complexes  
Because R7BP associates with R7 RGS·Gβ5 complexes (27), we next 
determined whether palmitate turnover regulates the trafficking of R7 RGS-Gβ5-R7BP 
heterotrimers. Split Venus-tagged forms of the R7 RGS protein RGS9-2 and Gβ5 were 
co-expressed transiently with RFP-R7BP in Neuro2A cells. In control cells these 
proteins co-localized extensively on the plasma membrane, whereas in HDFP-treated 
cells they co-localized on endomembrane compartments (Fig. 2J). Because RGS9-2·Gβ
5 complexes expressed transiently without R7BP localized diffusely to the cytoplasm 
and nucleoplasm (27), the effects of Palm B and HDFP indicated that inhibiting 
palmitate turnover on R7BP redistributes RGS9-2-Gβ5-R7BP heterotrimers from the 
plasma membrane to endomembranes.  
To address whether palmitate turnover is required for the function of R7 RGS·Gβ
5·R7BP complexes, we determined whether HDFP affects the ability of R7BP to 
allosterically modulate R7 RGS·Gβ5 complexes. This allosteric mechanism facilitates 
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association of R7 RGS·Gβ5 complexes with GIRK channels, as indicated by BRET 
experiments using cells co-expressing luciferase-tagged GIRK2c as donor and split 
Venus-tagged forms of R7 RGS proteins and Gβ5 as acceptors (26). Consistent with 
prior studies, FLAG-R7BP augmented BRET between GIRK2c and RGS9-2-Gβ5 
heterodimers ∼5-fold relative to controls lacking R7BP (Fig. 3A). HDFP significantly 
reduced BRET in R7BP-expressing cells (Fig. 3A) but did not affect BRET between 
GIRK2c and RGS9-2-Gβ5 heterodimers in cells lacking R7BP.  
Next, we determined whether HDFP affects R7BP-dependent regulation of GIRK 
channel activity by R7 RGS·Gβ5 complexes in cultured hippocampal pyramidal 
neurons. GIRK channels are opened by Gβγ subunits and closed by channel-bound 
Gi/oα subunits that have hydrolyzed GTP to GDP and reformed Gαβγ heterotrimers (37, 
38). By accelerating Gi/oα-mediated GTP hydrolysis, R7 RGS-Gβ5 complexes recruited 
to GIRK channels by R7BP facilitate channel closure (26). Accordingly, we treated 
hippocampal neurons from wild type and R7BP−/− mice with vehicle or HDFP and 
recorded whole-cell GIRK currents in response to application and subsequent washout 
of baclofen, a GABAB receptor agonist. Ablating R7BP or treating wild type neurons 
with HDFP impaired GIRK current deactivation kinetics (offset) similarly (Fig. 3, B and 
C). In R7BP−/− neurons, however, HDFP had a nonsignificant effect on GIRK current 
deactivation (Fig. 3, B and C). Because these results indicated that HDFP requires the 
presence of R7BP to affect GIRK current deactivation, they suggested that palmitate 
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turnover on R7BP is essential for R7 RGS·Gβ5 complexes to regulate GIRK channel 
activity.  
Whereas R7BP is required for HDFP to affect GIRK channel deactivation, we 
used a further approach to establish whether HDFP exerts its effects specifically by 
inhibiting depalmitoylation of R7BP rather than other proteins in this system such as 
Gi/oα subunits that also undergo palmitate turnover (39, 40). We determined whether 
R7BP bearing a polybasic region and geranylgeranylation motif (R7BP-GG) is functional 
and resistant to HDFP as assessed by the kinetics of GIRK channel deactivation. 
Neuro2A cells endogenously expressing RGS7·Gβ5 complexes were transiently 
transfected with GABAB receptors, GIRK2c, and either GFP as a control or GFP-tagged 
forms of wild type R7BP or R7BP-GG. Analysis of whole-cell GIRK currents upon 
application and subsequent washout of baclofen indicated that, in the absence of 
HDFP, palmitoylated and geranylgeranylated forms of GFP-R7BP were functionally 
equivalent as indicated by GIRK deactivation kinetics relative to GFP controls (Fig. 4). 
However, although GIRK channel deactivation kinetics in cells expressing wild type 
GFP-R7BP was sensitive to HDFP, they were resistant to HDFP in cells expressing 
GFP-R7BP-GG (Fig. 4). These and the preceding results therefore provided three 
independent lines of evidence that HDFP affects GIRK channel deactivation kinetics 
specifically by inhibiting palmitate turnover on R7BP. 
 
Serine Hydrolases Other Than or in Addition to APT1 and APT2 Depalmitoylate 
R7BP  
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APT1 is the only serine hydrolase shown to date that depalmitoylates proteins 
oriented toward the cell cytoplasm (10), suggesting that this enzyme and/or its close 
relative APT2 potentially depalmitoylate R7BP. We tested this hypothesis by knocking 
down APT1 and APT2 and/or inhibiting them with a potent, reversible inhibitor specific 
for each enzyme (compounds 21 and 1, respectively (33)). Efficient knockdown or 
inhibition of APT1 and -2 was achieved but failed to affect R7BP localization (Fig. 5, A–
D). Moreover, combining knockdown of APT1 and -2 with inhibitors of both enzymes did 
not impair R7BP depalmitoylation (Fig. 5E). These results indicated that serine 
hydrolases other than or in addition to APT1 and APT2 in neuronal cells depalmitoylate 
R7BP.  
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Figure 2-1.  Inhibition of R7BP depalmitoylation.  
A, R7BP depalmitoylation assays. Neuro2A cells stably expressing FLAG-R7BP were 
labeled with the palmitate analog 17-ODYA and chased 1 h with palmitate in the 
presence of vehicle, HDFP, or Palm B at the indicated concentrations. 17-ODYA 
incorporated into immunoprecipitated (IP) FLAG-R7BP was derivatized with TAMRA-
azide for fluorescence detection. Palmitoylation efficiency was quantified as the 
TAMRA-labeled FLAG-R7BP: total FLAG-R7BP ratio (n = 3 experiments). B, kinetics of 
R7BP depalmitoylation. Pulse-chase labeling of FLAG-R7BP was performed and 
quantified as described in A, except that samples from cells treated with vehicle or 
HDFP (10 μm) were prepared at the indicated time points of the chase. Upper panel, 
representative fluorescence image of FLAG-R7BP labeling by TAMRA-modified 17-
ODYA and total immunoprecipitated FLAG-R7BP detected by immunoblotting (IB). 
Lower panel, time course of FLAG-R7BP depalmitoylation in vehicle- and HDFP-treated 
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cells (n = 5 experiments). C and D, N-Ras and SNAP25 depalmitoylation assays. 
Neuro2A cells expressing GFP-N-Ras (C) or GFP-SNAP25 (D) were analyzed by pulse-
chase labeling experiments (n = 3) as described in A. Bars in A–D indicate S.E. *, p ≤ 
0.001 (Student's t test). 
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Figure 2-2. Effects of depalmitoylation inhibitors on intracellular trafficking of 
R7BP.  
Neuro2A cells transiently expressing the indicated GFP- or RFP-tagged proteins were 
treated with cycloheximide and then for 2 h with vehicle, Palm B, or HDFP (10 μm), 
followed by immunostaining for the indicated endomembrane markers and confocal 
fluorescence microscopy. Boxed areas in merged images correspond to regions shown 
at higher magnification (5×) in zoomed images. Diagonal orange lines in boxed areas 
indicate cell sections that were quantified by line scanning, as shown in adjacent 
graphs. A, GFP-R7BP (green) and a Golgi marker (intra-Golgi SNARE GS28; red). B, 
GFP-R7BP (green) and a trans-Golgi marker (RFP-GalT; red). C, GFP-R7BP (green) 
and an endosome marker (RFP-Rab5; red). D, time-lapse analysis of GFP-R7BP 
redistribution in cycloheximide-treated cells under the indicated conditions. E, 
redistribution of FLAG-tagged R7BP stably expressed at physiological levels in 
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Neuro2A cells. F, RFP-R7BP (red) and GFP-N-Ras (green). G, GFP-SNAP-25 (green) 
and a Golgi marker (GS28; red). H, geranylgeranylated GFP-R7BP-GG (green) and a 
Golgi marker (GS28; red). I, endomembrane accumulation of R7BP caused by activated 
Goα. Neuro2A cells were co-transfected with GFP-R7BP (green) and Goα that is 
constitutively active and RGS-resistant (Goα*, Goα-Q205L/G184S) and stained for a 
Golgi marker (GS28; red). J, split Venus-tagged forms of RGS9-2 and Gβ5 (green) and 
RFP-R7BP (red). Results shown are representative of at least three experiments. Scale 
bar, 10 μm. 
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Figure 2-3. Effects of depalmitoylation inhibitors on the interaction of R7 RGS·Gβ
5 complexes with GIRK2c and the regulation of GIRK activity.  
A, effect of HDFP on the ability of R7BP to promote interaction between RLuc8-tagged 
GIRK2c split Venus-tagged RGS-Gβ5 heterodimers indicated by BRET. Neuro2A cells 
transiently co-expressing GIRK2c-Rluc8, split Venus-tagged RGS9-Gβ5 heterodimers 
with or without R7BP, were treated 2 h with HDFP (10 μm) and analyzed in BRET 
assays. Data are expressed as net BRET values normalized to total fluorescence of the 
acceptor. B, effect of HDFP on GABAB receptor-evoked GIRK currents in hippocampal 
neurons isolated from wild type and R7BP−/− mice. Cultured neurons (days in vitro 14) 
were treated overnight with vehicle or HDFP (10 μm). Shown are representative traces 
of GABAB receptor agonist (baclofen)-evoked GIRK currents. Arrows indicate GIRK 
current deactivation (offset) upon baclofen washout. C, quantification of GIRK offset 
kinetics under the conditions indicated. Bars indicate mean ± S.E., n = 9 WT + vehicle, 
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9 R7BP−/− + vehicle, 7 WT + HDFP, 8 R7BP−/− + HDFP. **, p < 0.01; ***, p < 0.0001. 
n.s., not significant. 
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Figure 2-4. Palmitate turnover on R7BP is required for R7 RGS·Gβ5 complexes to 
regulate GIRK channel closure. 
GABAB receptor evoked GIRK currents in cells transfected with plasmids expressing 
GABAB receptor subunits 1a and 2, GIRK2c and GFP, GFP-tagged wild type R7BP 
(WT) or GFP-tagged geranylgeranylated R7BP (R7BP-GG), as indicated. A, 
representative traces of GIRK currents evoked by the GABAB receptor agonist 
(baclofen) in Neuro2A cells. GIRK currents were recorded in cells 2 h after treatment 
with vehicle or HDFP (10 μm) at 37 °C, as indicated. Arrows indicate GIRK current 
offset following baclofen washout. B, quantification of GIRK offset kinetics. GIRK offset 
kinetics in Neuro2A cells transfected and treated as in A. Offset components were fit 
with a single exponential function, and the time constant was used as a measure of 
offset kinetics. Bars indicate mean ± S.E., n = 25 GFP, 10 GFP + HDFP, 25 GFP-R7BP, 
17 GFP-R7BP + HDFP, 17 GFP-R7BP-GG, 12 GFP-R7BP-GG + HDFP, ***, p < 
0.0001. n.s., not significant.  
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Figure 2-5. Effect of APT1 and APT2 knockdown and inhibition on R7BP 
localization and depalmitoylation.  
A, APT1 and APT2 knockdown. Knockdown efficiency was determined by measuring 
the level of GFP-APT1 or -APT2 protein relative to FLAG-R7BP in Neuro2A cells 
transiently transfected with an APT1 shRNA-expressing plasmid or APT2 RNAi as 
compared with a control shRNA-expressing plasmid and control RNAi. B, effect of APT1 
and APT2 knockdown on localization of GFP-R7BP in Neuro2A cells stained for the 
Golgi marker GS28. C, inhibition of GFP-APT1 and -APT2 activity. Lysates of Neuro2A 
cells expressing GFP, GFP-APT1, or GFP-APT2 were treated 2 h with vehicle or 
specific reversible inhibitors of APT1 or APT2 (compounds 21 and 1, respectively; 10 μ
m), labeled with a fluorescent probe (PEGylated rhodamine-labeled fluorphosphonate) 
that covalently modifies only active enzyme, resolved by SDS-PAGE, and quantified by 
fluorescence scanning. Enzyme inhibition is indicated by reduction in fluorescent 
labeling. D, effect of APT1 and APT2 inhibition on GFP-R7BP localization. Neuro2A 
45 
 
cells transiently expressing GFP-R7BP were treated 2 h with vehicle or APT1- and 
APT2-specific inhibitors (compounds 21 and 1; 10 μm each), fixed, and stained for 
GS28. E, effect of simultaneous knockdown and inhibition of APT1 and APT2 on R7BP 
depalmitoylation. Neuro2A cells transiently expressing FLAG-R7BP and control RNAi or 
APT1- and -2-specific RNAi were pulse-labeled 2 h with 17-ODYA in the presence of 
vehicle or APT1 and APT2 inhibitors (compounds 21 and 1, 10 μm each) and chased 1 
h with unlabeled palmitate in the continued presence of vehicle or inhibitors. 17-ODYA 
incorporated into immunoprecipitated FLAG-R7BP before and after the chase was 
derivatized with TAMRA-azide for fluorescence detection and quantification. Quantified 
results in each panel are the average of at least three experiments. Bars indicate S.E. 
Scale bar, 10 μm. *, p < E-4. n.s., not significant. IB, immunoblot. 
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DISCUSSION 
 
Palmitate turnover is well established as a widespread biochemical process 
because hundreds of proteins, even in single cell types (19, 31, 41–44), are 
palmitoylated, and many proteins are dynamically palmitoylated or change 
palmitoylation status in response to cell activation or disease (11, 19, 22). However, 
whether palmitate turnover is essential for protein function or regulation remains poorly 
understood. As discussed below, our studies of R7BP establish a novel, essential 
function for palmitate turnover for regulating neuronal G protein-coupled receptor 
signaling and indicate that depalmitoylation in neuronal cells involves serine hydrolases 
other than or in addition to APT1.  
 We have found that palmitate turnover on R7BP is required for timely 
deactivation of Gi/o-gated GIRK channels by R7 RGS·Gβ5 complexes in neuronal cells. 
Palmitate turnover is required to accumulate R7BP on the plasma membrane, similar to 
H/N-Ras (7). Blunting palmitate turnover redistributes R7BP to endomembranes, 
thereby removing R7BP-bound R7-RGS·Gβ5 complexes from GIRK channels at the 
plasma membrane. Because R7 RGS·Gβ5 complexes are GTPase-activating proteins 
for Gi/oα subunits docked on GIRK channels, this redistribution process slows the rate 
of Gi/oα deactivation and consequent channel closure. Like H/N-Ras, stably 
palmitoylated R7BP may translocate by diffusion from the plasma membrane to 
endomembranes (21). Conversely, R7BP undergoing palmitate turnover could be 
utilized as a substrate for endomembrane-localized palmitoyltransferases that facilitate 
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its subsequent anterograde transport and steady state localization at the plasma 
membrane. Cycles of depalmitoylation and repalmitoylation of R7BP also may occur 
locally at the plasma membrane, similar to PSD-95 (18). Indeed, both R7BP and PSD-
95 are palmitoylated by DHHC2 (18, 28), which localizes to endomembranes and the 
plasma membrane.  
GIRK channel regulation by dynamic palmitoylation of R7BP may have important 
physiological functions. By hyperpolarizing neurons, GIRK channels provide a principal 
mechanism for inhibitory modulation of synaptic transmission by scores of Gi/o-coupled 
receptors and have been implicated in neurological disorders, including chronic pain, 
epilepsy, Parkinson disease, and Down syndrome (45). By impairing Gi/o deactivation, 
genetic ablation of R7BP augments GIRK activity and enhances the antinociceptive 
effects of morphine (26), which are evoked by Gi/o-coupled μ-opioid receptors and 
GIRK channels (46). By impairing R7BP localization and function at the plasma 
membrane, depalmitoylation inhibitors therefore may provide a means of enhancing 
morphine action in chronic pain or augmenting GIRK activity in neurological disorders.  
We have found that R7BP palmitoylation and trafficking are regulated strikingly 
by Gi/o signaling. Interruption of Gi/o signaling in neurons leads to accumulation of fully 
depalmitoylated R7BP in the nucleus (28), whereas sustained Gi/o signaling inhibits 
R7BP depalmitoylation and promotes endomembrane localization. Regulation of 
palmitate turnover on R7BP therefore may determine whether R7 RGS·Gβ5 complexes 
control Gi/o signaling at the plasma membrane or intracellular compartments or 
potentially transduce signals between compartments.  
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The serine hydrolases that depalmitoylate R7BP remain to be identified. Because 
knockdown, inhibition, knockout of the established acylprotein thioesterase APT1 and 
its relative APT2 did not affect R7BP localization or depalmitoylation in neuronal cells, 
these enzymes may be uninvolved. Alternatively, APT1 and/or APT2 could function 
redundantly with other serine hydrolases to depalmitoylate R7BP. Once the relevant 
acylprotein thioesterases have been identified, the mechanisms that regulate palmitate 
turnover on R7BP can be investigated.  
In conclusion, approaches analogous to those used by us and others (7, 47) 
should enable investigators to define the functions of palmitate turnover on specific 
proteins in a variety of biological processes. Such knowledge promises to reveal cellular 
and disease processes that potentially could be modulated by inhibitors of palmitate 
attachment or removal. 
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Chapter 3: The Identification and characterization of Abhd13 as a 
novel depalmitoylating enzyme 
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ABSTRACT 
 
The attachment of the palmitate moiety to both soluble and integral membrane proteins 
can have a number of functional effects including regulating its subcellular distribution, 
trafficking, and function.  Work in the field has shown that palmitoylation is an enzymatic 
process mediated by palmitoyl acyl transferases (PATs) and removed by palmitoyl 
protein thioesterases (PPTs). However, there are only two classes of enzymes [Protein 
palmitoyl thioesterase 1 (PPT1) and acyl protein thioesterase (APT1)] that have been 
characterized to have depalmitoylation activity and only APT1 is thought to regulate 
palmitate turnover on cytosolic proteins.  Here, we report the results of a 
depalmitoylation screen which identified Abhd13 as a novel thioesterase.  We show that 
Abhd13 is an integral membrane protein, localized to endomembranes, and that 
Abhd13 overexpression reduces palmitoylation of chimeric substrates in 
endomembrane compartments.  Our findings broaden the field by introducing a third 
depalmitoylation enzyme and challenging the current model of palmitoylation regulation.   
  
52 
 
 
INTRODUCTION 
 
In contrast to the large number of palmitoyl acyltransferases (PATs), only two 
classes of depalmitoylation enzymes (generally referred to as thioesterases) have been 
identified to date.  Protein palmitoyl thioesterase 1 (PPT1) and 2 (PPT2) are lysosmal 
enzymes and mediate protein depalmitoylation during protein degradation.  As PPT1/2 
enzymes are localized in the lysosome lumen, they are not thought to be involved in the 
dynamic regulation of palmitate turnover of cytosolic proteins.  As such, Duncan and 
Gilman searched for thioesterases that catalyze the depalmitoylation of a cytosolic 
protein (65).  They purified acyl protein thioesterase 1 (APT1, also known as 
lysophospholipase 1 ( LYPLA1)) from the cytosol of rat hepatocytes and found that it 
had depalmitoylation activity towards Gαi proteins in vitro.  In subsequent studies, APT1 
and its close homolog APT2 (64% sequence homology to APT1), have been shown to 
catalyze the depalmitoylation of several structurally different substrates in vitro (H/N-
Ras, Gai, eNOS, and RGS4).  Interestingly, APT1 was previously characterized as a 
lysophospholipase (89) but it was found to have several fold higher palmitoyl 
thioesterase activity (65).  Also, in the initial purification of APT1, they excluded using 
membrane fractions in order to separate the activity of PPT1 (integral membrane 
protein) from APT1 (cytosolic).  However, in doing so, they also excluded all other 
possible membrane-bound thioesterases other than PPT1 and PPT2.    
While the initial studies mainly focused on identifying APT1 substrates, more 
recent work has been directed towards the in vivo role of APT1.  In a recent study, 
Dekker and colleagues embarked on studying the role of APT1 in the depalmitoylation 
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of H-Ras in cells (75).  They looked at β-lactone derivatives, based on known inhibitors 
of structurally related gastric lipases, and identified palmitostatin B (palm B) as a new 
APT1-specific inhibitor. Activity-based protein profiling demonstrates that APT1 and 
APT2 are targets of palmitostatin B but this inhibitor also targets a number of other 
enzymes (90). Although palm B did have an effect on H-Ras localization, they did not 
assess if the palmitoylation state of H-Ras was affected; the effect of palm B on N-Ras 
depalmitoylation was demonstrated in our latest work in the previous chapter 
(68).   Furthermore, in another study, Martin et al. synthesized an inhibitor of palmitoyl 
thioesterases, hexadecylfluorophosphonate (HDFP), that is selective towards a subset 
of about 20 members of the large α/β-hydrolase family (Martin et al. 2011).  They 
demonstrated its activity against a subset of serine hydrolases in mouse brain 
membrane proteomes. They also identified the serine hydrolases that are targeted by 
HDFP which include APT1, APT2, PPT1, and a number of uncharacterized serine 
hydrolases.   
Given the vast number of proteins undergoing palmitate turnover and APT1 
being the only characterized depalmitoylation enzyme, it is unlikely that APT1 is the only 
thioesterase mediating depalmitoylation.  Our results from the previous chapter and the 
inhibitor studies mentioned above further support this notion.  Thus, we hypothesize that 
more distant relatives of APT1 in the large α/β-hydrolase family, which include lipases, 
proteases, and other uncharacterized proteins, may also function as deacylating 
enzymes.  Work in this chapter describes the identification and characterization of a 
serine hydrolase, Abhd13, as a novel depalmitoylatiion enzyme.   
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METHOD 
 
Cell Culture and Transfection: 
Neuro2A cells stably transfected with Abhd13-GFP or Abhd13(SA)-GFP and HEK293T 
cells were cultured as described in the previous chapter.  Abhd13-GFP and 
Abhd13(SA)-GFP cell lines were made in the APT1/2 double knockout cells described 
below.   
 
Reagents and Antibodies: 
The following antibodies were used: mouse anti-GFP (Abcam), mouse monoclonal anti-
FLAG M2 (Sigma), mouse anti-FLAG M2 beads (Sigma), mouse anti-GS28 (BD 
Transduction Laboratory), AlexaFluor 488-labeled goat anti-rabbit IgG and AlexaFluor 
568-labeled goat anti-mouse IgG (Invitrogen). Other reagents were as follows: 
tetramethylrhodamine (TAMRA)-azide (Lumiprobe); 17-octadecynoic acid (17-ODYA) 
(Cayman Chemical Company). The following chemicals were obtained from Sigma: 
DMSO, cycloheximide, phenylmethylsulfonyl fluoride (PMSF), poly-D-lysine, tris(2- 
carboxyethyl)phosphine hydrochloride (TCEP), tris-(benzyltriazolylmethyl)amine (TBTA) 
and CuSO4, and puromycin.  
 
Plasmids: 
Plasmids expressing GFP-tagged R7BP and GFP-tagged N-Ras have been published 
previously (68). Sources of other plasmids expressing various proteins were as follows: 
GFP-N-Ras and GFP-SNAP25 (M. Linder,Cornell University). Abhd13-3xFLAG-N-
Ras/R7BP/SNAP25 chimeric constructs were generated by taking the first 60 amino 
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acids of Abhd13, which contains the putative transmembrane domains, and fusing it to 
the full-length sequence of N-Ras, R7BP, or SNAP25 (Figure 3-5) separated by a linker 
region of six serine-glycine residues and a 3xFLAG epitope.  All plasmids were verified 
by DNA sequencing.   
 
Fluorescence Confocal Microscopy: 
Neuro2A cells seeded on poly-D-lysine (10 µg/ml)-coated coverslips were transfected 
with the indicated plasmids. At 24 h post-transfection, cells were fixed with 
paraformaldehyde (4%) for 10 min at room temperature. Cells were mounted in 
VECTASHIELD mounting medium (Vector Laboratories) and fluorescence images at 
different wavelengths were captured sequentially on an Olympus FV1200 microscope 
using Fluoroview software. Images were adjusted for brightness and contrast and 
analyzed using ImageJ software. 
 
Metabolic Labeling, Immunoprecipitation, and On-Bead Click Chemistry: 
Neuro2A cells transiently expressing the substrate of interest were labeled with 25 µM 
17-ODYA for 2 h in DMEM (Invitrogen) supplemented with 5% dialyzed FBS, 0.1 mM 
sodium pyruvate, and 0.1mM non-essential amino acids. Cells were washed with 
phosphate buffered saline (PBS) prior to being chased with media containing 200 µM 
palmitate for the indicated periods of time. Cells were then washed and suspended in 
lysis buffer via scrapping (PBS supplemented with 2.5 µM PMSF, 1x EDTA-free 
Complete Protease Inhibitors, and 1% Triton X100). Cleared lysates were 
immunoprecipitated overnight at 4°C with mouse anti-FLAG beads. After three washes 
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with lysis buffer, beads were suspended in PBS. Click-chemistry reaction protocols 
were adopted from previous publications (30, 31). Immunoprecipitated samples were 
incubated with click chemistry reagents (20 µM tetramethylrhodamine (TAMRA)-azide, 1 
mM TCEP, 100 µM TBTA, and 1 mM CuSO4) for 1 h at room temperature with periodic 
mixing. Reactions were stopped by adding of reducing SDS-PAGE sample buffer and 
heating for 5 min at 100°C. Samples were separated by SDS-PAGE and visualized by 
in-gel fluorescence analysis (Typhoon 9400 laser scanner, GE Healthcare) and Western 
blotting. Bands of interest were quantified using ImageJ (TAMRA fluorescence) or 
ImageLab (Bio-Rad, Western blotting).  Control experiments (not shown) were 
performed to establish the linear range of signal detection for both TAMARA 
fluorescence and chemiluminescence and all subsequent data were analyzed within the 
established linear range. 
 
In vitro PPT activity: 
HEK293T cells transiently expressing Abhd13-Flag enzymes or metabolically labeled 
substrates were lysed and Abhd13 or substrates were isolated using the 
immunoprecipitation protocol described above.  The proteins were eluted with 1X FLAG 
peptide in PBS.  APT1-His was purified from bacterial cells using the following protocol:  
transformed BL21 cells were induced with 0.5M IPTG and allow to express for 6 hours.  
The cells were then lysed via sonication in lysis buffer (PBS supplemented with 2.5 µM 
PMSF, 1x EDTA-free Complete Protease Inhibitors, and 1% Triton X100) and purified 
over His column.  The purified protein was eluted with 250 mM imidazole and dialyzed 
in lysis buffer.   
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Following purification, the enzymes and substrates were mixed together at the indicated 
concentration and incubated at 30°C for 2h.  The reaction was stopped and the degree 
of depalmitoylation on the substrate assessed using the protocol listed above.    
 
CRISPR-Cas9 knockout of APT1 and APT2 in N2a cells.   
To study the in vivo role of APT1 (mLYPLA1) and APT2 (mLYPLA1) in cells, CRISPR-
Cas9 system of genetic engineering was employed to generate APT1/2 double 
knockout Neuro2A cells.  This work was done through the Genome Engineering and 
IPSC Center (GEiC) at Washington University School of medicine using the following 
guide RNAs (gRNAs):   
mLypla1.g2 AGAATGGCATTCCTTCTAACNGG 
mLypla1.g3 TCCTTCTAACAGGATTATTTNGG 
 
mLypla2.g7 TCCTGCCAACCGGATCGTCCNGG 
mLypla2.g8 CCTGCCAACCGGATCGTCCTNGG 
 
The following PCR primers were used for sequencing in order to confirm the respective 
mutations: 
MS3.DS.mLYPLA1.F -  5' CCATCTTTAATATACTTTGCTTCTG 
MS3.DS.mLYPLA1.R -  5' CCAATTAGCCAAGATTCTGTAACAG 
 
MS4. DS.mLYPLA2.F - 5' GGGGGCAGGTAAGTGCTGTATAG 
MS4.DS.mLYPLA2.R -  3' CCCCATTCCCAAAGCACCAG 
 
Sequencing results show 1bp insertion/deletion in the APT1 alleles and several 
basepair deletion in APT2 alleles resulting in premature stop codons in the transcript or 
exon 6-9 fusion affecting the catalytic domain, respectively.      
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RESULTS 
 
Palmitate turnover is normal in APT1/2 knockout cells 
We previously attempted to address the in vivo role of APT1 by using APT1 and 
APT2 specific inhibitors in combination with siRNA knockdown and found undetectable 
change in the depalmitoylation rate of our lipid labeled R7BP substrate (54).  However, 
this approach potentially suffers from incomplete inhibition or knockdown of APT1 and 
does not take into account the possibility of compensation by other depalmitoylating 
enzymes. To more directly address the role of APT1 and -2 in cells, we knocked out 
both APT1 and, its homolog, APT2 in neuroblastoma (N2a) cells using the CRISPR-
Cas9 system.  More specifically, guide RNAs were targeted toward both APT1 and 
APT2 loci.  The resulting double knockout clone was verified by sequencing and was 
found to harbor a basepair deletion or insertion in the sixth exon of APT1 and several 
deletions affecting exon 7, 8, and 9 of APT2.   
We used the APT1/2 double knockout (DKO) cells to assess if the palmitate 
turnover rate on FLAG-N-Ras and FLAG-R7BP is affected by the absence of APT1 and 
APT2. We observe no differences in their rates of palmitate turnover in parental versus 
APT1/2 DKO cells (Figure 3-1A and B); thus, suggesting that APT1 and APT2, while 
having in vitro activity toward N-Ras, does not play essential roles in N-Ras 
depalmitoylation in vivo.  Our experimental results corroborate those reported by 
Duncan and Gilman (2002) in which APT1 knockout in yeast resulted in loss of activity 
toward lipid-modified mammalian Gαi protein but not H-Ras suggesting that another 
thioesterase might be acting on H-Ras (91). 
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Depalmitoylation screen identified Abhd13 as a novel thioesterase 
We recently demonstrated that both palm B and HDFP, broad depalmitoylation 
inhibitors, inhibited N-Ras and R7BP palmitate turnover as measured by an established 
method using the palmitate analog 17-octadecynoic acid (17-OYDA) in neuroblastoma 
(Neuro2A) cells (68).   Additionally, our results from inhibition and knockout of APT1 and 
-2 suggest that serine hydrolases other than, or in addition to, APT1 and APT2 mediate 
R7BP depalmitoylation.  To identify this novel thioesterase(s), we screened a small set 
of HDFP-sensitive hydrolases (92) for their effect on R7BP and N-Ras depalmitoylation 
using our in vitro palmitate turnover assay.   More specifically, we cloned these highly 
HDFP-sensitive hydrolases (>50% inhibition) and co-expressed them with either FLAG-
N-Ras, FLAG-R7BP, or FLAG-SNAP25.  Following 2 h pulse-labeling with the palmitate 
analog 17-ODYA, the cells were lysed and 17-ODYA-labeled proteins conjugated with 
an azide-linked fluorescent dye (TAMRA) by using click chemistry for fluorescence 
detection.   Our results show that some enzymes, when overexpressed, have little to no 
noticeable effect on N-Ras palmitoylation while others, Abhd13 and Abhd16a in 
particular, had increased N-Ras depalmitoylation which is comparable to that observed 
with overexpression of APT1, a known PPT for N-Ras proteins (Figure 3-2).  Similar 
effects are also observed for R7BP palmitoylation state but not for SNAP25.  
 
ABHD13: A novel depalmitoylating enzyme 
Our in vitro biochemical assays show that Abhd13 is a novel depalmitoylation 
enzyme and is more potent and selective than APT1.  First, we co-expressed Abhd13-
GFP or GFP-APT1 enzyme with our substrates of interest to determine their effect on 
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the steady state palmitoylation of these proteins.  We observe roughly 80% reduction in 
17-ODYA label incorporation in FLAG-N-Ras proteins when co-expressed with Abhd13 
(Figure 3-3A and B).  Similar effects are observed with FLAG-R7BP (~50% reduction) 
while there is no noticeable effect on FLAG-SNAP25 labeling; thus, suggesting that 
Abhd13 is selective towards N-Ras and R7BP as substrates.  In contrast, the catalytic-
dead mutant (S193A) abolished Abhd13 depalmitoylation activity toward both N-Ras 
and R7BP.  Furthermore, to determine whether Abhd13 is preferentially selective 
toward singly palmitoylated proteins, hence having higher activity toward N-Ras as 
opposed to R7BP, we are planning to examine its activity toward GFP-H-Ras proteins.  
We hypothesize that H-Ras will be depalmitoylated to a similar extent as R7BP, both 
dually palmitoylated, and, thus, explain the higher activity towards singly palmitoylated 
N-Ras. Similarly, Abhd13 should have a higher activity towards the singly palmitoylated 
R7BP (CS/SC) mutants as compared to wildtype R7BP protein.   
To further confirm the above results, the enzymatic activity and substrate 
specificity of Abhd13 enzyme was examined in vitro using purified proteins.  Both 17-
ODYA labeled substrates and Abhd13-FLAG enzyme were transiently expressed and 
immunoprecipitated separately from HEK293T cells.  His-tagged APT1 was expressed 
and purified from bacteria as the amount of protein obtained from mammalian 
expression were not sufficient to observe any effect on depalmitoylation (data not 
shown).  The isolated enzymes and substrates were incubated at 30°C for 2h prior to 
assaying for the amount of 17-ODYA label removed from the substrates.  The result of 
this assay corroborate our earlier findings in that Abhd13 has high depalmitoylation 
activity towards N-Ras, some activity towards R7BP, and no activity toward SNAP25, at 
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least at the concentrations tested.  Taken together, these data suggest that Abhd13 
function as a bona fide deacylating enzyme.  Moreover, it was observed that Abhd13 is 
about 50 times more potent than APT1 in depalmitoylating N-Ras (Figure 3-3C and D).  
Lastly, high concentrations of APT1 has activity towards all three substrates tested.  
 
Abhd13 is an integral membrane protein that localizes to endomembranes 
Sequence analysis shows that Abhd13, like APT1/2 and PPT1/2, is a member of 
the α/β hydrolase protein superfamily and is conserved across many different eukaryotic 
lineages (Figure 3-4A)(93,94).  There is a remarkable sequence homology between 
mouse Abhd13 and its orthologs, containing roughly 96% primary sequence similarity 
with human and rat Abhd13, 46.4% similarity to Bem46 in Drosophila, and 37.2% 
similarity to YNL320W in S.cerevisiae. However, despite the high degree of similarity, to 
our knowledge, the functional role of these proteins has not been characterized.   
Transmembrane prediction algorithm (TMHMM 2.0) using mouse Abhd13 
sequence suggest that Abhd13 contain at least one, possibly two, transmembrane 
domain (Figure 3-4B).  Both transient and stable expression of Abhd13-GFP further 
indicate that Abhd13 is an integral membrane protein and is localized to 
endomembranes.  Transient expression of Abhd13-GFP in N2a cells suggest that 
Abhd13 is found in ER or early Golgi compartments (Figure 3-4C).  The topology 
relative to this endomembrane is hypothesized to have the catalytic domain oriented 
toward the cytosolic surface of the membrane as deduced by data shown below using 
Abhd13-chimeric substrates. However, a more extensive study of the intracellular 
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localization and topology of Abhd13 is underway by looking at its localization with 
appropriate organelle-specific marker proteins.   
 
Abhd13 overexpression reduces palmitoylation in endomembrane compartments  
To determine the thioesterase activity of Abhd13 in cells, we looked at palmitate 
turnover of Abhd13-chimeric substrates. The labeling assays were done with these 
chimeric substrates because we wanted to target our substrate of interest, which are all 
normally PM localized at steady state levels, to the same compartment as Abhd13, 
which is found in endomembrane compartments.  The chimeric substrates were made 
by fusing the first 60 amino acids of Abhd13, containing the TM domains, to the N-
terminal of the FLAG-tagged N-Ras, R7BP, or SNAP25 (Figure 3-5A).  Confocal images 
confirm that these chimeric-substrates are targeted to the same compartment as 
Abhd13 (Figure 3-5B).   
We next looked at palmitate turnover on these chimeric substrates using our 
established assay of pulse labeling with the palmitate analog 17-ODYA for 2h and 
chasing with palmitate for the indicated period of time.  Our results show no label 
incorporation for Abhd13Nt-N-Ras when co-expressed with Abhd13-GFP (Figure 3-5C).  
However, normal labeling was observed for the catalytic-dead version of Abhd13 in 
which the catalytic serine (S193A) is mutated to alanine.  The chimeric R7BP and 
SNAP25 substrates did have label incorporation, albeit at lower levels as compared to 
the GFP control or Abhd13(SA)-GFP samples, but the turnover rates were not affected 
by Abhd13-GFP.  Interestingly, protein levels were much lower with Abhd13 co-
expression as compared to GFP control and Abhd13(SA)-GFP samples.  Also, since we 
64 
 
observed label incorporation on these chimeric substrates, we hypothesize that the 
catalytic domain of Abhd13 is found on the cytoplasmic side of the membrane which is 
the same as the catalytic domains of DHHC enzymes required for labeling.    
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Figure 3-1: Palmitate turnover is normal in APT1/2 knockout cells. 
 (A). Pulse-chase labeling of FLAG-N-Ras and FLAG-R7BP in APT1/2 knockout and 
parental Neuro2A cells. Cells were labeled with the palmitate analog 17-ODYA for 2 h 
and chased with palmitate for the indicated period of time. 17-ODYA incorporated into 
immunoprecipitated (IP) substrates was derivatized with TAMRA-azide for fluorescence 
detection. Upper panel, representative fluorescence image of FLAG-N-Ras or FLAG-
R7BP labeling by TAMRA-modified 17-ODYA.  Lower panel, total immunoprecipitated 
substrates detected by immunoblotting (IB).  (B) Palmitoylation efficiency was quantified 
as the TAMRA-label:total protein ratio (n = 3 experiments). Bars indicate S.E.M. 
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Figure 3-2. Effect of candidate HDFP-sensitive serine hydrolase overexpression 
on steady-state plamitoylation. 
 
FLAG-tagged N-Ras, R7BP, or SNAP25 were transiently expressed with GFP or the 
indicated HDFP-sensitive serine hydrolases.  Whole cell lysates were prepared and 17-
ODYA incorporated proteins were derivatized with TAMRA-azide for fluorescence 
detection.  Label incorporation is observed for all palmitoylated proteins but the 
overexpression of the substrate of interest is several fold higher than the background 
proteins.  Upper panel, representative fluorescence image of FLAG-tagged N-Ras, 
R7BP, and SNAP25 labeled by TAMRA-modified 17-ODYA.  Middle panel, substrates 
67 
 
detected by immunoblotting (IB).  Lower panel, expression of GFP-tagged serine 
hydrolases.  Since both substrate and enzyme are FLAG-tagged, a separate dish was 
transfected with equal amount of plasmid to check for enzyme expression.   
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Figure 3-3.  Abhd13 is more potent and selective depalmitoylating enzyme than 
APT1 in vitro.  
 
(A) FLAG-tagged N-Ras, R7BP, or SNAP25 was transiently expressed in HEK293T 
cells with either GFP, Abhd13-GFP, the catalytic-dead version of Abhd13-GFP (S193A), 
or GFP-APT1 constructs.  48 h after transfection, cells were labeled with the palmitate 
analog 17-ODYA for 2 h and the 17-ODYA-labeled substrates immunoprecipitated (IP) 
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and tagged with TAMRA-azide for fluorescence detection. Upper panel, representative 
fluorescence image of substrate labeling by TAMRA-modified 17-ODYA.  Middle panel, 
total immunoprecipitated substrates detected by immunoblotting (IB). Lower panel, 
expression of Abhd13 and APT1 enzymes. (B) Palmitoylation labeling was quantified as 
the TAMRA-labeled:total protein ratio (n = 3 experiments). Bars indicate S.E.M. * 
p≤0.05. (C) In vitro depalmitoylation assay of Abhd13 and APT1 activity towards the 
substrates used in (A).  17-ODYA labeled substrates were incubated with varying 
amount of enzymes for 2 h at 30°C.  (D) The amount of 17-ODYA label remaining was 
assayed using the method described above.  N=3 for N-Ras (10 ng Abhd13-FLAG), 
N=2 for R7BP and SNAP25 (10 ng Abhd13-FLAG), N=1 for all other enzyme 
concentrations.  Error bars represent SD.      
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Figure 3-4. Abhd13 is an integral membrane protein that localizes to 
endomembranes 
 
(A) Primary sequence comparison between Abhd13 orthologs and APT1.  Sequence 
alignment were made using ClustalW2 and modified with Jalview 2.8.2 using the 
following accession numbers: NP_116248.2 (ABHD13, H. sapiens), NP_081144.1 
(Abhd13, M. musculus), NP_001258001.1 (Abhd13, R. norvegicus), NP_001032774.1 
(Abhd13, D. rerio), XP_003388451.1 (Abhd13, A. queenslandica), NP_477372.1 
(Bem46, D. melanogaster), NP_014079.1 (YNL320W, S. cerevisiae), NP_006321.1 
(LYPLA1, H. sapiens), NP_032892.1 (Lypla1, M. musculus).  Highlighted are the 
predicted transmembrane region for Abhd13 as well as the lipase-like GXSXG motif 
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containing the catalytic serine residue.  Dark and light purple indicate 100% or =/> 70% 
sequence homology, respectively, as compared to the human ABHD13. Astricks denote 
APT1 catalytic triad site (Ser-119, Asp-174, and His-208). (B) Tramsmebrane prediction 
using TMHMM v. 2.0 using mouse Abhd13 sequence.  (C)  Endomembrane localization 
of transiently expressed Abhd13-GFP in N2a cells.   ER-RFP is the fusion of mRFP and 
KDEL ER retention sequence in the pCDNA3.1 vector (95).    
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Figure 3-5.  Abhd13 overexpression reduces palmitoylation in endomembrane 
compartments.  
 
(A) Schematic of the chimeric Abhd13 N-terminal-substrate fusion proteins. The 
transmembrane region of Abhd13 was fused to 3xFlag-tagged N-Ras, R7BP, or 
SNAP25.  Six Glycine-Serine amino acids serves as a linker between the two domains.  
(B) The chimeric substrates co-localize with Abhd13-GFP with high efficiency.  R-values 
represent Pearson coefficients.  (C) Palmitate turnover on the chimeric substrates using 
the assay described in Figure 3-1.  Upper panel, representative fluorescence image of 
chimeric-Abhd13-N-Ras, R7BP, or SNAP25 protein labeling by TAMRA-modified 17-
ODYA.  Lower panel, substrates detected by immunoblotting (IB). (D) Quantification of 
the bands of interest in (C) (n=3) as described in Figure 3-1.    
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DISCUSSION 
 
Many signaling proteins undergo reversible translocation between plasma 
membrane and the cytoplasm.  For most of these proteins, their mode of cycling is 
mediated through reversible palmitoylation, the attachment of 16-carbon moiety to a 
cysteine residue.  Furthermore, several of these dynamically palmitoylated proteins are 
regulated by signal transduction in which agonist stimulation promote palmitate 
turnover.  However, whether palmitate turnover is essential for protein function or 
regulation remains poorly understood. Our studies of R7BP described in the previous 
chapter establish a novel, essential function for palmitate turnover for regulating 
neuronal G protein-coupled receptor signaling and indicate that depalmitoylation in 
neuronal cells involves serine hydrolases other than or in addition to APT1. The enzyme 
that depalmitoylate R7BP remains to be identified and, consequently, the mechanisms 
that regulate palmitate turnover on R7BP also remains to be explored. 
In attempt to identify this acylprotein thioesterase, our screen of HDFP-sensitive 
serine hydrolase resulted in the identification of Abhd13 as a novel depalmitoylating 
enzyme.  Similar to APT1/2 and PPT1/2, Abhd13 belongs to the large α/β-hydrolase 
family.  However, in contrast to the cytoplasmic localization of APT1, Abhd13 is an 
integral membrane protein that localizes to endomembranes.  We hypothesize that 
Abhd13 is localized to either ER or Golgi compartment based on our overexpression 
studies; however, further co-staining of endogenous Abhd13 with compartment specific-
markers will further confirm the specific endomembrane compartment.  We also 
postulate that the catalytic domain of Abhd13 is facing the cytoplasmic side of the 
membrane as determined from our chimeric Abhd13-N-Ras, R7BP, or SNAP25 fusion 
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substrates (Figure 3-5). The fact that these chimeric substrates are palmitoylated 
suggest that the substrates are accessible to DHHC enzymes which are oriented with 
their catalytic DHHC domain on the cytosolic side of the membrane.   
Furthermore, our in vitro biochemical assays demonstrate that Abhd13 is more 
potent and selective than APT1. Indeed, Abhd13 is about 50 times more active towards 
N-Ras when compared to APT1 as assayed using purified enzymes (Figure 3-3B).  
However, we observe moderate activity (50%) towards R7BP and no activity toward 
SNAP25.  In contrast, at high concentrations, APT1 was found have activity toward all 
three substrates tested.  Whether Abhd13 have similar non-specific activity at high 
concentration remains to be determined.   
Additional work is needed to determine the precise localization of Abhd13, 
substrate specificity, in vivo activity, and mode of regulation.  We have made antibody 
towards Abhd13 and will look at endogenous Abhd13 localization and tissue 
expression.  We also knocked out Abhd13 in APT1/2 DKO cells using the CRISPR-cas9 
system to look at the in vivo role of Abhd13 on palmitate turnover. Since we do not 
know at present the endogenous substrates of Abhd13, we will initially use our Abhd13-
chimeric substrates to look at palmitate turnover.  Additionally, we can also look to see if 
RGS4 is a substrate for Abhd13.  Palmitoylation at Cys2 protects RGS4 protein from 
degradation by stably promoting its PM localization (41).  As such, if Abhd13 is found to 
have deacylation activity towards RGS4, then the in vivo role of Abhd13 can further be 
tested by measuring its effect on RGS4 protein levels.  The altered RGS4 protein levels 
can have direct effect on Gαi-mediated calcium signaling.   
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 Aside from APT1 and -2, the identification of Abhd13 as a novel palmitoyl 
thioesterases has a broad significance considering that protein palmitoylation is a 
common lipid modification for many proteins and play an important role in modulating 
their trafficking and activity. In a recent study, Rocks and colleagues reported that 
depalmitoylation activity is broadly distributed throughout the cell, has rapid on/off 
kinetics, and suggest that the rapid turnover cycle may provide a mean for mislocalized 
palmitoylated protein to be redirected to the Golgi-PM sorting pathway (46).  This 
unidirectional movement of palmitoylated protein is well documented for a number of 
dynamically palmitoylated proteins including N-/H-Ras.  As such, the inhibition of 
depalmitoylation with palm B altered the subcellular distribution of semisynthetic N- and 
H-Ras to endomembrane compartments (75).  Thus, the current model of palmitoylation 
regulation is that following palmitoylation at the Golgi, in this case, Ras proteins 
randomly sample all membranes. The deacylation activity of APT1, distributed 
throughout the cell, promote the retrieval and directional transport of palmitoylated 
proteins back to the secretory pathway.  Additionally, APT1 is itself palmitoylated and 
this palmitoylation state is thought to allow for access to membrane-localized substrates 
(96).   Although APT1 has activity towards a number of structurally different substrates 
in in vitro assays, there is no specific consensus sequence for APT1 recognition and as 
a result is thought to be nonselective.  Consequently, the field is presented with several 
questions: how is deacylation controlled? What factors mediate APT1 substrate 
specificity?  Are there acyl thioesterases beyond APT1 and APT2? 
 The identification of Abhd13 broadens the current model of palmitoylation 
regulation by introducing localized regulation which would allow for a more fine-tuned 
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spatiotemporal control of dynamics protein acylation. The compartmentalized activity of 
Abhd13 challenges the current model of palmitoylation regulation which is based on the 
distributive activity of APT1, discussed more extensively in the next chapter.  Akin to the 
redundancy observed with DHHC enzymes with multiple subcellular distribution, 
Abhd13, APT1, and other unidentified depalmitoylation enzymes provide additional 
mode of regulation.   
Furthermore, the differential localization of these enzymes can regulate localized 
events in a signal dependent manner or that each thioesterase have activity towards 
only a limited subset of proteins.   Similar to DHHC enzymes, protein thioesterases can 
share a core catalytic domain and differ in their regulatory regions (N- or C-terminus 
sequence) that afford differential substrate specificity or influence their localization, or 
both. Since all the protein thioesterase identified to date belongs to the α/β serine 
hydrolase family, it is very possible that they mediate their activity through a conserved 
thioesterase domain. As we identify more depalmitoylating enzymes and their 
corresponding substrates, we can further speculate on their specific mode of action and 
regulation.   
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Chapter 4: Conclusions and Future Perspectives 
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Current Challenges and Future Perspectives 
 
To fully interrogate the mechanism and regulation of protein palmitoylation, it is 
essential to know the enzymes and have specific inhibitors to alter their activity.  The 
field of palmitoylation has been severely disadvantaged in both fronts until recent events 
dramatically accelerated the pace of discovery.  First, advancements in non-radioactive 
chemical labeling methodologies have significantly enhanced the sensitivity of our 
detection method as well as enrichment and identification of palmitoylated proteins.  
Secondly, the discovery of palmitoyl transferases and thioesterases greatly improved 
our understanding of the mechanism of protein palmitoylation.  These discoveries also 
added interest to the field because a number of palmitoyl transferase and thioesterases 
have been associated with several diseases including cancer, Huntington’s disease, 
and neuronal ceroid lipofuscinosis (71–74).  Lastly, the lack of specific inhibitors also 
limited our pace of discovery in which we mainly rely on broad inhibitors (such as 2-
bromopalmitate, cerulenin, palmitostatin B, HDFP, etc.) which can have many off-target 
effects.  However, the current depalmitoylation inhibitors at hand have been a useful 
tool for studying the in vivo role of depalmitoylation on cellular processes (as shown in 
chapter 2) and as a means for identifying novel thioesterases (chapter 3).  
Nevertheless, the development of more specific inhibitors would further improve our 
understanding of the mechanism and regulation of protein palmitoylation in normal and 
diseased states.    
Given the important role of palmitoylation in the localization and function of many 
signaling proteins, it is surprising that we still have much to learn about the underlying 
mechanism.  This slow progress towards understanding the functional role of 
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palmitoylation, as stated earlier, has in large part been due to limitations of our 
experimental methodology in which determining the palmitoylation status of many 
proteins has been a tedious process.  Considering the wide variety of the sequence 
contexts in which palmitoylation can occur, predicting palmitoylated protein from 
sequence alone is not possible.  Thus, to more fully appreciate the overall scope of this 
important modification in physiological processes, it is vital to know all the proteins that 
are palmitoylated in the cell.  To this end, recent proteomics studies are continuing to 
expand the number of proteins modified with palmitate (97).  Also, the reversible nature 
of palmitoylation, akin to the role of protein phosphorylation, suggest that it could 
regulate the activity, as well as localization, of many signaling proteins.  Thus, our 
recent studies (chapter 2) aimed at understanding how palmitate-cycling is regulated 
and how this impact protein function and downstream events.   
Our recent works broaden the scope of biological processes regulated by 
palmitate turnover on specific target proteins.  Our laboratory have previously shown 
that plasma membrane targeting of the R7 RGS protein family is mediated by their 
association with R7BP (R7 binding protein) which translocates the R7-Gβ5-R7BP 
complex from the PM to the nucleus depending on its palmitoylation state (43,98). At 
steady state, palmitate turnover occurs rapidly on R7BP and can be negatively 
regulated by Gi/o signaling (43).  Inhibition of depalmitoylation via hexadecyl 
fluorophosphonate (HDFP) or palmostatin B (palm B) caused R7BP to redistribute from 
the plasma membrane to endomembrane compartments, dissociated R7BP-bound R7 
RGS complexes from Gi/o-gated G protein-regulated inwardly rectifying K+ (GIRK) 
channels and delayed GIRK channel closure (chapter 2, (68)). This, in turn, would 
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suggest an elegant manner by which G protein activity can be modulated through the 
acylation state of the R7BP.    
Other studies in the field corroborates our findings in that palmitate turnover can 
modulate physiological processes. For example, recent studies show that PSD-95 
(postsynaptic density protein 95) palmitoylation is dynamic, which means that palmitate 
cycling on PSD-95 proteins can effect postsynaptic AMPA receptor clustering (99,100).  
PSD-95 is a scaffold protein which serves as a platform for the assembly or clustering of 
receptors, ion channels, and associated signaling proteins to the post-synaptic 
membranes and, consequently, plays a critical role in synaptic transmission and 
plasticity (99).  Blocking PSD-95 palmitoylation via the palmitoylation inhibitor 2-
bromopalmitate disperses PSD-95 clusters suggesting that palmitoylation cycling is 
necessary for proper localization (100). Glutamate-induced synaptic activation, on the 
other hand, results in increased PSD95 depalmitoylation and AMPA receptor 
endocytosis (100). Similar to Gα proteins, agonist-induced palmitate turnover on PSD-
95 suggests that an unidentified pamitoyl thioesterase (PPT) is one of the downstream 
effectors and negative regulator of the signaling pathway. Thus, an enigmatic question 
in the field has been whether other stimulus-induced palmitoylation changes are due to 
regulated depalmitoylation.  Our study, discussed above and in chapter 2, provides one 
answer and is the first to demonstrate how depalmitoylation can have a dramatic impact 
on downstream signaling events.  Nevertheless, since a number of proteins are 
dynamically palmitoylated, the precise balance of PAT and PPT activity in regulating the 
homeostasis of signaling proteins at the membrane require further study.  
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  Although the field of palmitoylation greatly benefited from the identification of 
several palmitoylation and depalmitoylation enzymes, there remain many unanswered 
questions.  As there are many proteins that undergo palmitoylation and only a few 
enzyme-substrate pairing established, it remains to be determined how substrate 
recognition takes place.  It is not clear whether substrate recognition is mediated by 
sequence, accessory proteins, proximal acylation (such as myristoylation or 
prenylation), or substrate proximity or localization.  In the case of mammalian DHHC 
enzymes, there is redundancy in acylation activity with variable substrate specificity  
(101).  The individual expression of DHHC enzymes with substrates of interest show 
that palmitoylation of some substrates is dependent on a single enzyme whereas others 
can be modified by several enzymes (101,102). Looking at the structural component of 
the substrates and their cognate DHHC enzymes, it appears that substrate recognition 
can be mediated by multiple recognition elements such as through accessory proteins 
(DHHC9/GCP16) or proximal lipidation which brings the substrate in proximity of their 
respective DHHC enzyme.   Whether similar substrate specificity strategies also apply 
to depalmitoylation enzymes remain to be determined.   
 The steady acylation state of palmitoylated proteins and signaling-induced 
palmitate turnover on palmitoylated proteins would suggest that regulation of 
palmitoylation lies at the depalmitoylation step.   Whereas the protein palmitoyl 
thioesterases (PPTs) that remove palmitate from proteins were identified several years 
prior to DHHC enzymes (103), much less is known about the identity and substrate 
specificity of PPT enzymes. Thus far, only two classes of thioesterases [Protein 
Palmitoyl Thioesterase 1 (PPT1) and Acyl Protein Thioesterase 1 (APT1)] have been 
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shown to catalyze the removal of palmitate from proteins in vitro (65,103).  PPT1 was 
demonstrated to have enzymatic activity toward H-Ras and Gα proteins but subsequent 
studies showed that PPT1 is a lysosomal depalmitoylase with the primary role of 
removing palmitate from protein being degraded in the lysosome (103–105).    Indeed, 
mutation of PPT1 was found to cause infantile neuronal ceroid lipofuscinosis (INCL) 
which leads to the granular deposits of lipid-modified proteins (ceroid) in neurons (104).  
APT1, on the other hand, is a more promising candidate for regulating dynamic 
palmitate cycling of intracellular proteins.  Like, PPT1, APT1 is a member of the highly 
conserved α/β hydrolase family and has been documented to have depalmitoylation 
activity towards a number of substrates (Ga protein, Ras, eNOS, RGS4, SNAP23, etc.) 
in in vitro assays (65,91,106,107).   However, the in vivo role of APT1 in regulating 
depalmitoylation remains to be elucidated.  Also, APT1 is itself palmitoylated and this 
modification is postulated to allow it to gain access to its membrane-associated 
substrates. However, in comparison to the large family of DHHC enzymes mediating 
palmitoylation, it is unlikely that APT1 can confer enough specificity towards all the 
palmitoylated proteins in the cell to be the only deacylating enzyme.  APT1/2 deletion in 
cells doesn’t affect viability which would suggest that either it is dispensable for viability 
or that other, yet unidentified, thioesterases (like Abhd13) are compensating for APT1/2.  
Our work in the identification of Abhd13 as a novel depalmitoylation enzyme 
advances the field in several ways. First, for many years it was thought that APT1 was 
not the only enzyme to catalyze the depalmitoylation of cytosolic substrates.  The 
identification of Abhd13 adds to the layer of complexity of palmitate regulation as will be 
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discussed shortly.  Second, the assay used in the identification of Abhd13 can similarly 
be used to look for more depalmitoylating enzymes.   Although we only detected 
depalmitoylation activity by Abhd13, and perhaps Abhd16a, towards N-Ras and R7BP, 
it is very possible that the other HDFP-sensitive enzymes used in our study can have 
activity toward other palmitoylated substrates not tested (such as PSD95 or integral 
membrane proteins).  Screening these enzymes for activity towards various 
palmitoylated substrates will advance the field by not only identifying more 
depalmitoylating enzymes but also allow us to draw conclusions regarding substrate 
specificity.  Lastly, using palm B and HDFP as a starting point, the development of 
specific inhibitors will also progress the field by giving us a tool to dissect the in vivo role 
of these enzymes in regulating dynamic protein palmitoylation. Activity-based protein 
profiling assays (108) can be used with these enzymes to both look at inhibitor 
specificity and characterize enzyme function.   
The current model of palmitoylation regulation is that constitutive 
depalmitoylation occurs ubiquitously on all membranes and this, in turn, maintains the 
directional transport and localization of palmitoylated proteins (Figure 4-1)(109).  The 
deacylation activity of APT1, a cytosolic protein distributed throughout the cell, is 
postulated to promote the retrieval and directional transport of mislocalized 
palmitoylated proteins back to the secretory pathway. However, the identification of 
Abhd13 (chapter 3) as another candidate depalmitoylation enzyme challenges this 
model by introducing localized, spatiotemporal regulation of depalmitoylation (Figure 4-
1).  First, Abhd13 deacylation activity may promote the removal of mislocalized 
palmitoylated proteins (compartmentalized kinetic editing) and be involved in forward 
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trafficking.  Accordingly, genetic ablation of Abhd13 in cell should result in 
endomembrane accumulation of palmitoylated proteins in the same compartment as 
Abhd13, presumably early Golgi as that is where Abhd13 is tentatively is postulated to 
be localized. We have generated Abhd13 knockout (KO) N2a cell lines in the APT1/2 
KO background and will examine any defect in vesicular trafficking or protein 
mislocalization. Premilinary evidence in our laboratory supports this notion in which we 
observe increased GFP-N-Ras endomembrane accumulation in Abhd13 KO cells while 
N-Ras localization is not affected in N2a or APT1/2 KO parental cells.  Furthermore, the 
localization of R7BP does not seem to be effected.  This confirms our in vitro findings 
that Abhd13 preferentially works on N-Ras proteins but further work is necessary to 
show that Abhd13 is sufficient to mediate this effect.   
 
Figure 4-1.  Dynamic palmitoylation via distributed and endomembrane-localized 
depalmitoylating enzymes.  
(Old Model) APT1 activity is distributed throughout the cell and constitutive 
depalmitoylation occurs ubiquitously on all membranes. (New Model) Endomembrane-
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localized depalmitoylating enzymes suggest localized, spatiotemporal regulation of 
depalmitoylation.   
 
 Second, Abhd13, like PPT1/2, is an integral membrane protein and should have 
easy access to membrane-associated palmitoylated proteins.  As described earlier, H- 
and N-Ras isoforms require dynamic palmitoylation to maintain a steady state plasma 
membrane (PM) localization, which is essential for transducing extracellular proliferative 
signals.  As a result, Ras activation is generally thought to take place at the plasma 
membrane; accordingly, inhibition of PM localization of H/N-Ras is being explored as a 
potential therapeutic target (see below).  However, emerging evidence in the literature 
suggest that Ras is also activated in response to mitogen on a variety of 
endomembrane compartments including Golgi and ER (110,111).  Since we have 
shown that Abhd13 depalmitoylate N-Ras in vitro and its localization is perturbed in 
Abhd13 knockout cells, inhibition of Abhd13 could be a potential therapeutic target for 
cancer treatment.   
Lastly, Abhd13 carries out its function in a compartment specific manner which is 
in contrast to the distributive depalmitoylation activity of APT1.  The current model of 
palmitoylation regulation is based on APT1 (cytosolic protein) but the identification of a 
second, integral membrane enzyme allow for a more fine-tuned spatiotemporal control 
of dynamics protein acylation. This is particularly important in the case of polarized cells 
such as neurons which have distinct morphological structures (dendrites, soma, and 
axons) that enables them to carry out specialized functions.  Bi-directional changes in 
synaptic protein palmitoylation levels following agonist stimulation have been reported 
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(112).  Furthermore, we and others have demonstrated that a number of proteins (Gα, 
PSD-95, R7BP, and others) are depalmitoylated in response to agonist stimulation 
(113,100,43). Thus, taken together, the identification of Abhd13, and other unidentified 
enzymes, broaden the current model to include localized depalmitoylation activity 
(Figure 4-1).       
 
Aberrant regulation of protein palmitoylation and depalmitoylation can have 
deleterious effects on protein function and have been implicated for a number of 
proteins.  The dysregulation can be either with mutations on the substrates or abnormal 
expression of palmitoyl transferases or thioesterases.  For instance, palmitoylation is 
essential for the proper localization of Ras proteins and Ras mutations are common in 
many human cancers (114).  Oncogenic H-Ras undergo an increased rate of palmitate 
turnover as compared to wildtype H-Ras proteins (115).  This leads to the notion that 
oncogenic H-Ras activity can be modulated by preventing dynamic acylation as a 
potential therapeutic strategy.  Indeed, inhibitors against farnesyl transferase have been 
developed but has not been effective in clinical trials due to perhaps it being 
geranylgeranylated instead (116). It is possible that depalmitoylation inhibitors might 
prove to be a more effective treatment for Ras-mediated tumor.  Also, if it is 
demonstrated to have in vivo activity toward Ras proteins, then Abhd13 could be a 
possible target for such treatment.    
 Similar modulation of depalmitoylation enzymatic activity could also serve as an 
effective treatment for Huntington’s disease.  Huntington’s disease is a neurological 
disorder which is caused by an autosomal dominant mutation in the huntingtin protein 
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(Htt) leading to an expanded number of glutamine residues within an existing 
polyglutamine tract. There exists a palmitoylation site within this region that is present in 
both wildtype and mutant Htt protein; however, the altered form has decreased acylation 
levels which corresponds to increased aggregation and insoluble inclusion body 
formation within neuronal cells (117).  Overexpression of DHHC17/HIP14, which is 
responsible for palmitoylating Htt protein, reduces the number of inclusion bodies in 
cells expressing mutant Htt proteins (118).  Thus, the development of inhibitors to block 
the activity of the unidentified thioesterase mediating Htt protein depalmitoylation would 
be a useful therapeutic strategy in the treatment of Huntington’s disease.   
 
In conclusion, protein palmitoylation is emerging as a major player in the 
regulation of cellular processes.  However, further work is needed to unravel the full 
impact of this modification on protein function and downstream signaling events.  The 
work presented in the previous chapters advances this field by providing evidence for 
the role of depalmitoylation in regulating biological processes as well as the 
identification of a novel depalmitoylating enzyme (Abhd13).  However,  the interplay 
between of PATs and PPTs, their precise localization, their specificity and mode of 
regulation will need to be elucidated.  Nevertheless, while initially studied for their role in 
membrane targeting of proteins, several studies are pointing to for a more interesting 
role for protein palmitoylation with many unanswered questions which will, undoubtedly, 
be addressed in the coming years.   
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